



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification⁵ : C12N 15/54, 9/12, 1/21 // (C12N 1/21, C12R 1/21)	A1	(11) International Publication Number: WO 92/06202 (43) International Publication Date: 16 April 1992 (16.04.92)
(21) International Application Number: PCT/US91/07076 (22) International Filing Date: 26 September 1991 (26.09.91) (30) Priority data: 590,490 28 September 1990 (28.09.90) US (60) Parent Application or Grant (63) Related by Continuation US 590,490 (CIP) Filed on 28 September 1990 (28.09.90) (71) Applicant (for all designated States except US): CETUS CORPORATION [US/US]; 1400 Fifty-Third Street, Emeryville, CA 94608 (US).		(72) Inventors; and (75) Inventors/Applicants (for US only) : GELFAND, David, H. [US/US]; 6208 Chelton Drive, Oakland, CA 94611 (US). LAWYER, Frances, C. [US/US]; 6641 Saroni Drive, Oakland, CA 94611 (US). ABRAMSON, Richard, D. [US/US]; 5901 Broadway, #30, Oakland, CA 94618 (US). GREENFIELD, I., Lawrence [US/US]; 36 Wildwood Court, Pleasant Hill, CA 94523 (US). REICHERT, Fred, L. [US/US]; 2845 Carmel Street, Oakland, CA 94602 (US). (74) Agent: SIAS, Stacey, R.; Cetus Corporation, 1400 Fifty-Third Street, Emeryville, CA 94608 (US). (81) Designated States: AT (European patent), AU, BE (European patent), CA, CH (European patent), DE (European patent), DK (European patent), ES (European patent), FR (European patent), GB (European patent), GR (European patent), IT (European patent), JP, LU (European patent), NL (European patent), SE (European patent), US. Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: PURIFIED THERMOSTABLE NUCLEIC ACID POLYMERASE ENZYME FROM <i>THERMOSIPHO AFRICANUS</i> (57) Abstract <p>A purified thermostable enzyme is derived from the eubacterium <i>Thermosipho africanus</i>. The enzyme has DNA polymerase activity, reverse transcriptase activity, and optionally 5' → 3', and/or 3' → 5' exonuclease activity. The enzyme can be native or recombinant, and may be used with primers and nucleoside triphosphates in a temperature-cycling chain reaction where at least one nucleic acid sequence is amplified in quantity from an existing sequence.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MG	Madagascar
AU	Australia	FI	Finland	ML	Mali
BB	Barbados	FR	France	MN	Mongolia
BE	Belgium	GA	Gabon	MR	Mauritania
BF	Burkina Faso	GB	United Kingdom	MW	Malawi
BG	Bulgaria	GN	Guinea	NL	Netherlands
BJ	Benin	GR	Greece	NO	Norway
BR	Brazil	HU	Hungary	PL	Poland
CA	Canada	IT	Italy	RO	Romania
CF	Central African Republic	JP	Japan	SD	Sudan
CG	Congo	KP	Democratic People's Republic of Korea	SE	Sweden
CH	Switzerland	KR	Republic of Korea	SN	Senegal
CI	Côte d'Ivoire	LJ	Liechtenstein	SU ⁺	Soviet Union
CM	Cameroon	LK	Sri Lanka	TD	Chad
CS	Czechoslovakia	LU	Luxembourg	TC	Togo
DE ⁺	Germany	MC	Monaco	US	United States of America
DK	Denmark				

⁺ Any designation of "SU" has effect in the Russian Federation. It is not yet known whether any such designation has effect in other States of the former Soviet Union.

PURIFIED THERMOSTABLE NUCLEIC ACID POLYMERASE ENZYME FROM THERMOSIPHO AFRICANUS

Field of the Invention

The present invention relates to a purified, thermostable DNA polymerase
5 purified from the thermophilic bacteria Thermosipho africanus (Taf) and means for
isolating and producing the enzyme. Thermostable DNA polymerases are useful in
many recombinant DNA techniques, especially nucleic acid amplification by the
polymerase chain reaction (PCR).

Background Art

10 Extensive research has been conducted on the isolation of DNA polymerases
from mesophilic microorganisms such as E. coli. See, for example, Bessman et al.,
1957, J. Biol. Chem. 223:171-177, and Buttin and Kornberg, 1966, J. Biol. Chem.
241:5419-5427.

Much less investigation has been made on the isolation and purification of DNA
15 polymerases from thermophiles such as Taf. Kaledin et al., 1980, Biokhimiya 45:644-
651, disclose a six-step isolation and purification procedure of DNA polymerase from
cells of Thermus aquaticus YT-1 strain. These steps involve isolation of crude extract,
DEAE-cellulose chromatography, fractionation on hydroxyapatite, fractionation on
DEAE-cellulose, and chromatography on single-strand DNA-cellulose. The molecular
20 weight of the purified enzyme is reported as 62,000 daltons per monomeric unit.

A second purification scheme for a polymerase from Thermus aquaticus is
described by Chien et al., 1976, J. Bacteriol. 127:1550-1557. In this process, the
crude extract is applied to a DEAE-Sephadex column. The dialyzed pooled fractions
are then subjected to treatment on a phosphocellulose column. The pooled fractions are
25 dialyzed and bovine serum albumin (BSA) is added to prevent loss of polymerase
activity. The resulting mixture is loaded on a DNA-cellulose column. The pooled
material from the column is dialyzed and analyzed by gel filtration to have a molecular
weight of about 63,000 daltons and by sucrose gradient centrifugation of about 68,000
daltons.

30 The use of thermostable enzymes, such as those described in U.S. Patent No.
4,889,818, to amplify existing nucleic acid sequences in amounts that are large
compared to the amount initially present was described United States Patent Nos.
4,683,195 and 4,683,202, which describe the PCR process, both disclosures of which
are incorporated herein by reference. Primers, template, nucleoside triphosphates, the
35 appropriate buffer and reaction conditions, and polymerase are used in the PCR

process, which involves denaturation of target DNA, hybridization of primers, and synthesis of complementary strands. The extension product of each primer becomes a template for the production of the desired nucleic acid sequence. The two patents disclose that, if the polymerase employed is a thermostable enzyme, then polymerase
5 need not be added after every denaturation step, because heat will not destroy the polymerase activity.

United States Patent No. 4,889,818, European Patent Publication No. 258,017, and PCT Publication No. 89/06691, the disclosures of which are incorporated herein by reference, all describe the isolation and recombinant expression
10 of an ~94 kDa thermostable DNA polymerase from Thermus aquaticus and the use of that polymerase in PCR. Although T. aquaticus DNA polymerase is especially preferred for use in PCR and other recombinant DNA techniques, there remains a need for other thermostable polymerases.

Accordingly, there is a desire in the art to produce a purified, thermostable DNA
15 polymerase that may be used to improve the PCR process described above and to improve the results obtained when using a thermostable DNA polymerase in other recombinant techniques such as DNA sequencing, nick-translation, and even reverse transcription. The present invention helps meet that need by providing recombinant expression vectors and purification protocols for a DNA polymerase from Taf.

20 Summary of the Invention

Accordingly, the present invention provides a purified thermostable enzyme that catalyzes combination of nucleoside triphosphates to form a nucleic acid strand complementary to a nucleic acid template strand. The purified enzyme is the DNA polymerase I activity from Taf. In a preferred embodiment, the enzyme is isolated from
25 Taf strain OB-7 (DSM 5309). This purified material may be used in a temperature-cycling amplification reaction wherein nucleic acid sequences are produced from a given nucleic acid sequence in amounts that are large compared to the amount initially present so that the sequences can be manipulated and/or analyzed easily.

The gene encoding Taf DNA polymerase I enzyme from Taf has also been
30 identified and cloned and provides yet another means to prepare the thermostable enzyme of the present invention. In addition to the portions of the gene encoding the Taf enzyme, derivatives of these gene portions encoding Taf DNA polymerase I activity are also provided.

The invention also encompasses a stable enzyme composition comprising a
35 purified, thermostable Taf enzyme as described above in a buffer containing one or more non-ionic polymeric detergents.

Finally, the invention provides a method of purification for the thermostable polymerase of the invention. This method involves preparing a crude extract from Taf or recombinant host cells, adjusting the ionic strength of the crude extract so that the DNA polymerase dissociates from nucleic acid in the extract, subjecting the extract to at least one chromatographic step selected from hydrophobic interaction chromatography, DNA binding protein affinity chromatography, nucleotide binding protein affinity chromatography, and cation, anion, or hydroxyapatite chromatography. In a preferred embodiment, these steps are performed sequentially in the order given above. The nucleotide binding protein affinity chromatography step is preferred for separating the DNA polymerase from endonuclease proteins.

Brief Description of the Figures

Figure 1 shows various PCR profiles.

Figure 2 shows the effect of various PCR profiles on amplification.

Figure 3 shows various PCR profiles.

Detailed Description of the Invention

The present invention provides DNA sequences and expression vectors that encode Taf DNA polymerase I. To facilitate understanding of the invention, a number of terms are defined below.

The terms "cell", "cell line", and "cell culture" can be used interchangeably and all such designations include progeny. Thus, the words "transformants" or "transformed cells" include the primary transformed cell and cultures derived from that cell without regard to the number of transfers. All progeny may not be precisely identical in DNA content, due to deliberate or inadvertent mutations. Mutant progeny that have the same functionality as screened for in the originally transformed cell are included in the definition of transformants.

The term "control sequences" refers to DNA sequences necessary for the expression of an operably linked coding sequence in a particular host organism. The control sequences that are suitable for procaryotes, for example, include a promoter, optionally an operator sequence, a ribosome binding site, and possibly other sequences. Eucaryotic cells are known to utilize promoters, polyadenylation signals, and enhancers.

The term "expression system" refers to DNA sequences containing a desired coding sequence and control sequences in operable linkage, so that hosts transformed with these sequences are capable of producing the encoded proteins. To effect

transformation, the expression system may be included on a vector; however, the relevant DNA may also be integrated into the host chromosome.

5 The term "gene" refers to a DNA sequence that comprises control and coding sequences necessary for the production of a recoverable bioactive polypeptide or precursor. The polypeptide can be encoded by a full length gene sequence or by any portion of the coding sequence so long as the enzymatic activity is retained.

10 The term "operably linked" refers to the positioning of the coding sequence such that control sequences will function to drive expression of the protein encoded by the coding sequence. Thus, a coding sequence "operably linked" to control sequences refers to a configuration wherein the coding sequences can be expressed under the direction of a control sequence.

15 The term "mixture" as it relates to mixtures containing Taf polymerase refers to a collection of materials which includes Taf polymerase but which can also include other proteins. If the Taf polymerase is derived from recombinant host cells, the other proteins will ordinarily be those associated with the host. Where the host is bacterial, the contaminating proteins will, of course, be bacterial proteins.

20 The term "non-ionic polymeric detergents" refers to surface-active agents that have no ionic charge and that are characterized for purposes of this invention, by an ability to stabilize the Taf enzyme at a pH range of from about 3.5 to about 9.5, preferably from 4 to 8.5.

25 The term "oligonucleotide" as used herein is defined as a molecule comprised of two or more deoxyribonucleotides or ribonucleotides, preferably more than three, and usually more than ten. The exact size will depend on many factors, which in turn depends on the ultimate function or use of the oligonucleotide. The oligonucleotide may be derived synthetically or by cloning.

30 The term "primer" as used herein refers to an oligonucleotide which is capable of acting as a point of initiation of synthesis when placed under conditions in which primer extension is initiated. An oligonucleotide "primer" may occur naturally, as in a purified restriction digest or be produced synthetically. Synthesis of a primer extension product which is complementary to a nucleic acid strand is initiated in the presence of four different nucleoside triphosphates and the Taf thermostable enzyme in an appropriate buffer at a suitable temperature. A "buffer" includes cofactors (such as divalent metal ions) and salt (to provide the appropriate ionic strength), adjusted to the desired pH. For Taf polymerase, the buffer preferably contains 1 to 3 mM of a
35 magnesium salt, preferably $MgCl_2$, 50 to 200 μM of each nucleotide, and 0.2 to 1 μM of each primer, along with 50 mM KCl, 10 mM Tris buffer (pH 8.0-8.4), and 100

μg/ml gelatin (although gelatin is not required, and should be avoided in some applications, such as DNA sequencing).

5 A primer is single-stranded for maximum efficiency in amplification, but may alternatively be double-stranded. If double-stranded, the primer is first treated to separate its strands before being used to prepare extension products. The primer is usually an oligodeoxyribonucleotide. The primer must be sufficiently long to prime the synthesis of extension products in the presence of the polymerase enzyme. The exact length of a primer will depend on many factors, such as source of primer and result desired, and the reaction temperature must be adjusted depending on primer length and
10 nucleotide sequence to ensure proper annealing of primer to template. Depending on the complexity of the target sequence, an oligonucleotide primer typically contains 15 to 35 nucleotides. Short primer molecules generally require lower temperatures to form sufficiently stable complexes with template.

A primer is selected to be "substantially" complementary to a strand of specific
15 sequence of the template. A primer must be sufficiently complementary to hybridize with a template strand for primer elongation to occur. A primer sequence need not reflect the exact sequence of the template. For example, a non-complementary nucleotide fragment may be attached to the 5' end of the primer, with the remainder of the primer sequence being substantially complementary to the strand. Non-
20 complementary bases or longer sequences can be interspersed into the primer, provided that the primer sequence has sufficient complementarity with the sequence of the template to hybridize and thereby form a template primer complex for synthesis of the extension product of the primer.

The terms "restriction endonucleases" and "restriction enzymes" refer to
25 bacterial enzymes which cut double-stranded DNA at or near a specific nucleotide sequence.

The terms "thermostable polymerase" and "thermostable enzyme" refer to an enzyme which is stable to heat and is heat resistant and catalyzes (facilitates) combination of the nucleotides in the proper manner to form primer extension products
30 that are complementary to a template nucleic acid strand. Generally, synthesis of a primer extension product begins at the 3' end of the primer and proceeds in the 5' direction along the template strand, until synthesis terminates.

The Taf thermostable enzyme of the present invention satisfies the requirements for effective use in the amplification reaction known as the polymerase chain reaction or
35 PCR. The Taf enzyme does not become irreversibly denatured (inactivated) when subjected to the elevated temperatures for the time necessary to effect denaturation of double-stranded nucleic acids, a key step in the PCR process. Irreversible denaturation

for purposes herein refers to permanent and complete loss of enzymatic activity. The heating conditions necessary for nucleic acid denaturation will depend, e.g., on the buffer salt concentration and the composition and length of the nucleic acids being denatured, but typically range from about 90°C to about 105°C for a time depending
 5 mainly on the temperature and the nucleic acid length, typically from a few seconds up to four minutes. Higher temperatures may be required as the buffer salt concentration and/or GC composition of the nucleic acid is increased. The Taf enzyme does not become irreversibly denatured for relatively short exposures to temperatures of about 90°C-100°C.

10 The Taf thermostable enzyme has an optimum temperature at which it functions that is higher than about 45°C. Temperatures below 45°C facilitate hybridization of primer to template, but depending on salt composition and concentration and primer composition and length, hybridization of primer to template can occur at higher temperatures (e.g., 45-70°C), which may promote specificity of the primer
 15 hybridization reaction. The Taf enzyme exhibits activity over a broad temperature range from about 37°C to 90°C.

The present invention provides DNA sequences encoding the thermostable DNA polymerase I activity of Taf. The encoded amino acid sequence has homology to portions of the thermostable DNA polymerases of Thermus species Z05 (TZ05),
 20 Thermotoga maritima (Tma), Thermus aquaticus (Taq) strain YT1, T. thermophilus (Tth), and Thermus species sps17 (Tsps17). The entire Taf coding sequence and the deduced amino acid sequence is depicted below as SEQ ID NO: 1. The amino acid sequences is also listed as SEQ ID NO: 2. For convenience, the amino acid sequence of this Taf polymerase is numbered for reference. Portions of the 5' and 3' noncoding
 25 regions of the Taf DNA polymerase I gene are also shown.

```

      1 GAATTCTTGAAGAAGGGACTTTAAATACTAAGAGGTTTTTTAACT
      46 TAGATGGAAATGTTTACAAAAAGGGTGCATTAGATGAGAAAACAA
      91 AGGAATTAATGGGACTTGTTGCTTCAATGGTTTTAAGGTGTGATG
     136 ATTGTATTACTTATCATATGATAAGGTGTGCACAACTTGGAGTTA
     30 181 GTGATGAAGAATTTTTTGAACTTTTGATGTGGCATTGATAGTTG
     226 GAGGTTCAATAGTAATTCCTCATTTAAGACGTGCTGTAAATTGC

     271 TTGAGGATATCAGGGAGATGCAAAAAAATGGGAAAGATGTTTCTA
           1 MetGlyLysMetPheLeu
     35 316 TTTGATGGAACCTGGATTAGTATACAGAGCATTTTATGCTATAGAT
           7 PheAspGlyThrGlyLeuValTyrArgAlaPheTyrAlaIleAsp
  
```


361 CAATCTCTTCAAACCTTCGTCTGGTTTACACACTAATGCTGTATAC
22 GlnSerLeuGlnThrSerSerGlyLeuHisThrAsnAlaValTyr

5 406 GGACTTACTAAAATGCTTATAAAATTTTAAAAGAACATATCAGT
37 GlyLeuThrLysMetLeuIleLysPheLeuLysGluHisIleSer

451 ATTGGAAAAGATGCTTGTGTTTTTGTTTTAGATTCAAAGGTGGT
52 IleGlyLysAspAlaCysValPheValLeuAspSerLysGlyGly

10 496 AGCAAAAAAGAAAGGATATTCTTGAAACATATAAAGCAAATAGG
67 SerLysLysArgLysAspIleLeuGluThrTyrLysAlaAsnArg

541 CCATCAACGCCTGATTTACTTTTAGAGCAAATTCATATGTAGAA
82 ProSerThrProAspLeuLeuLeuGluGlnIleProTyrValGlu

15 586 GAACTTGTTGATGCTCTTGAATAAAAGTTTAAAAATAGAAGGC
97 GluLeuValAspAlaLeuGlyIleLysValLeuLysIleGluGly

631 TTTGAAGCTGATGACATTATTGCTACGCTTCTAAAAAATTTGAA
20 112 PheGluAlaAspAspIleIleAlaThrLeuSerLysLysPheGlu

676 AGTGATTTTGAAAAGGTAAACATAATACTGGAGATAAAGATCTT
127 SerAspPheGluLysValAsnIleIleThrGlyAspLysAspLeu

25 721 TTACAACTTGTTTCTGATAAGGTTTTTGTGGAGAGTAGAAAGA
142 LeuGlnLeuValSerAspLysValPheValTrpArgValGluArg

766 GGAATAACAGATTTGGTATTGTACGATAGAAATAAAGTGATTGAA
30 157 GlyIleThrAspLeuValLeuTyrAspArgAsnLysValIleGlu

811 AAATATGGAATCTACCCAGAACAATTCAAAGATTATTTATCTCTT
172 LysTyrGlyIleTyrProGluGlnPheLysAspTyrLeuSerLeu

856 GTCGGTGATCAGATTGATAATATCCCAGGAGTTAAAGGAATAGGA
35 187 ValGlyAspGlnIleAspAsnIleProGlyValLysGlyIleGly

901 AAGAAAACAGCTGTTTCGCTTTTGAAAAAATATAATAGCTTGGAA
202 LysLysThrAlaValSerLeuLeuLysLysTyrAsnSerLeuGlu

40 946 AATGTATTAAAAAATATTAACCTTTTGACGGAAAAATTAAGAAGG
217 AsnValLeuLysAsnIleAsnLeuLeuThrGluLysLeuArgArg

991 CTTTTGGAAGATTCAAAGGAAGATTTGCAAAAAGTATAGAACTT
232 LeuLeuGluAspSerLysGluAspLeuGlnLysSerIleGluLeu

5 1036 GTGGAGTTGATATATGATGTACCAATGGATGTGGAAAAGATGAA
247 ValGluLeuIleTyrAspValProMetAspValGluLysAspGlu

1081 ATAATTTATAGAGGGTATAATCCAGATAAGCTTTTAAAGGTATTA
262 IleIleTyrArgGlyTyrAsnProAspLysLeuLeuLysValLeu

10 1126 AAAAAGTACGAATTTTCATCTATAATTAAGGAGTTAAATTTACAA
277 LysLysTyrGluPheSerSerIleIleLysGluLeuAsnLeuGln

1171 GAAAAATTAGAAAAGGAATATATACTGGTAGATAATGAAGATAAA
292 GluLysLeuGluLysGluTyrIleLeuValAspAsnGluAspLys

15 1216 TTGAAAAAAGTTGCAGAAGAGATAGAAAAATACAAAAGTTTTC
307 LeuLysLysLeuAlaGluGluIleGluLysTyrLysThrPheSer

1261 ATTGATACGGAAACAACCTTCACTTGATCCATTTGAAGCTAACTG
20 322 IleAspThrGluThrThrSerLeuAspProPheGluAlaLysLeu

1306 GTTGGGATCTCTATTTCCACAATGGAAGGGAAGGCGTATTATATT
337 ValGlyIleSerIleSerThrMetGluGlyLysAlaTyrTyrIle

25 1351 CCGGTGTCTCATTTTGGAGCTAAGAATATTTCCAAAAGTTTAATA
352 ProValSerHisPheGlyAlaLysAsnIleSerLysSerLeuIle

1396 GATAAATTTCTAAAACAAATTTTGCAAGAGAAGGATTATAATATC
367 AspLysPheLeuLysGlnIleLeuGlnGluLysAspTyrAsnIle

30 1441 GTTGGTCAGAATTTAAAATTTGACTATGAGATTTTAAAAGCATG
382 ValGlyGlnAsnLeuLysPheAspTyrGluIlePheLysSerMet

1486 GGTTTTTCTCCAAATGTTCCGCATTTTGATACGATGATTGCAGCC
35 397 GlyPheSerProAsnValProHisPheAspThrMetIleAlaAla

1531 TATCTTTTAAATCCAGATGAAAAACGTTTTAATCTTGAAGAGCTA
412 TyrLeuLeuAsnProAspGluLysArgPheAsnLeuGluGluLeu

40 1576 TCCTTAAAATATTTAGGTTATAAAATGATCTCGTTTGATGAATTA
427 SerLeuLysTyrLeuGlyTyrLysMetIleSerPheAspGluLeu

1621 GTAAATGAAAATGTACCATTGTTTGGAAATGACTTTTCGTATGTT
442 ValAsnGluAsnValProLeuPheGlyAsnAspPheSerTyrVal

45 1666 CCACTAGAAAGAGCCGTTGAGTATTCCTGTGAAGATGCCGATGTG
457 ProLeuGluArgAlaValGluTyrSerCysGluAspAlaAspVal

1711 ACATACAGAATATTTAGAAAGCTTGGTAGGAAGATATATGAAAAT
50 472 ThrTyrArgIlePheArgLysLeuGlyArgLysIleTyrGluAsn

1756 GAGATGGAAAAGTTGTTTTACGAAATTGAGATGCCCTTAATTGAT
487 GluMetGluLysLeuPheTyrGluIleGluMetProLeuIleAsp

1801 GTTCTTTCAGAAATGGAATAAATGGAGTGTATTTTGATGAGGAA
502 ValLeuSerGluMetGluLeuAsnGlyValTyrPheAspGluGlu

5 1846 TATTTAAAAGAATTATCAAAAAAATATCAAGAAAAAATGGATGGA
517 TyrLeuLysGluLeuSerLysLysTyrGlnGluLysMetAspGly

1891 ATTAAGGAAAAAGTTTTTGAGATAGCTGGTGAAACTTTCAATTTA
532 IleLysGluLysValPheGluIleAlaGlyGluThrPheAsnLeu

10 1936 AACTCTTCAACTCAAGTAGCATATATACTATTTGAAAAATTAAAT
547 AsnSerSerThrGlnValAlaTyrIleLeuPheGluLysLeuAsn

1981 ATTGCTCCTTACAAAAAACAGCGACTGGTAAGTTTTCAACTAAT
562 IleAlaProTyrLysLysThrAlaThrGlyLysPheSerThrAsn

15 2026 GCGGAAGTTTTAGAGAAGAACTTTCAAAAGAACATGAAATTGCAAAA
577 AlaGluValLeuGluGluLeuSerLysGluHisGluIleAlaLys

2071 TTGTTGCTGGAGTATCGAAAGTATCAAAAATTAAAAAGTACATAT
592 LeuLeuLeuGluTyrArgLysTyrGlnLysLeuLysSerThrTyr

2116 ATTGATTCAATACCGTTATCTATTAATCGAAAAACAAACAGGGTC
607 IleAspSerIleProLeuSerIleAsnArgLysThrAsnArgVal

25 2161 CATACTACTTTTCATCAAACAGGAACCTTCTACTGGAAGATTAAAGT
622 HisThrThrPheHisGlnThrGlyThrSerThrGlyArgLeuSer

2206 AGTTCAAATCCAAATTTGCAAAATCTTCCAACAAGAAGCGAAGAA
637 SerSerAsnProAsnLeuGlnAsnLeuProThrArgSerGluGlu

30 2251 GGAAAAGAAATAAGAAAAGCAGTAAGACCTCAAAGACAAGATTGG
652 GlyLysGluIleArgLysAlaValArgProGlnArgGlnAspTrp

2296 TGGATTTTAGGTGCTGACTATTCTCAGATAGAACTAAGGGTTTTA
667 TrpIleLeuGlyAlaAspTyrSerGlnIleGluLeuArgValLeu

35 2341 GCGCATGTAAGTAAAGATGAAAATCTACTTAAAGCATTAAAGAA
682 AlaHisValSerLysAspGluAsnLeuLeuLysAlaPheLysGlu

40 2386 GATTTAGATATTCATACAATTACTGCTGCCAAAATTTTTGGTGTT
697 AspLeuAspIleHisThrIleThrAlaAlaLysIlePheGlyVal

2431 TCAGAGATGTTTGTAGTGAACAAATGAGAAGAGTTGGAAAGATG
712 SerGluMetPheValSerGluGlnMetArgArgValGlyLysMet

45 2476 GTAAATTTTGCAATTATTTATGGAGTTTCACCTTATGGTCTTTCA
727 ValAsnPheAlaIleIleTyrGlyValSerProTyrGlyLeuSer

2521 AAGAGAATTGGTCTTAGTGTTCAGAGACTAAAAAATAATAGAT
742 LysArgIleGlyLeuSerValSerGluThrLysLysIleIleAsp

50 2566 AACTATTTTAGATACTATAAAGGAGTTTTTGAATATTTAAAAAGG
757 AsnTyrPheArgTyrTyrLysGlyValPheGluTyrLeuLysArg

2611 ATGAAAGATGAAGCAAGGAAAAAAGGTTATGTTACAACGCTTTTT
772 MetLysAspGluAlaArgLysLysGlyTyrValThrThrLeuPhe

5 2656 GGAAGGCGCAGATATATTCCACAGTTAAGATCGAAAAATGGTAAT
787 GlyArgArgArgTyrIleProGlnLeuArgSerLysAsnGlyAsn

2701 AGAGTTCAAGAAGGAGAAAGAATAGCTGTAAACACTCCAATTCAA
802 ArgValGlnGluGlyGluArgIleAlaValAsnThrProIleGln

10 2746 GGAACAGCAGCTGATATAATAAAGATAGCTATGATTAATATTCAT
817 GlyThrAlaAlaAspIleIleLysIleAlaMetIleAsnIleHis

2791 AATAGATTGAAGAAGGAAAATCTACGTTCAAAAATGATATTGCAG
832 AsnArgLeuLysLysGluAsnLeuArgSerLysMetIleLeuGln

15 2836 GTTCATGACGAGTTAGTTTTTTGAAGTGCCCGATAATGAACTGGAG
847 ValHisAspGluLeuValPheGluValProAspAsnGluLeuGlu

2881 ATTGTAAGAGATTTAGTAAGAGATGAGATGGAAAATGCAGTTAAG
20 862 IleValLysAspLeuValArgAspGluMetGluAsnAlaValLys

2926 CTAGACGTTCTTTTAAAAGTAGATGTTTATTATGGAAAAGAGTGG
877 LeuAspValProLeuLysValAspValTyrTyrGlyLysGluTrp

25 2971 GAATAATGGCTGGGGTAAAGGAATTTAAAGATCTAATAGAATTAA
892 Glu

3016 ATGAATATGTTACAAAAAAATAGAATTGACGGGTCTTACAAGTG
3061 AGACCTTTAGGTTTTATGCAGATGTTGTTAGAGCCAATAACCATT

30 3106 CTACAGGTTTGTATATTGATGTTTCACAACCTTATACTGCAAAGA
3151 ATGGAACAAGAAATATTGAAATTACTGTGTATGTACCTAGATATC
3196 TTGCACCAAAAATTTTGAAGTTATAAAAGTTTCTAATGTTAAGG
3241 AACTTGTTGGGAAAAAATGGATTTTTCAAGGGAGACTTTCTTTTTT
3286 TCAGAGATAGAATGAGTTTTACCTTCTATGCAGATACAATAGCTC

35 3331 CGATGGGAGAATCTGAGATTGAAAAAGAAGAAAAGAAATATTGA
3376 AAGAGCTTGAGGTTAGAAATTTATTAATGAAAGAAAAGCATGATC
3421 TTTCTGAATTGCCACCAATAAAAAAGATTGCTATTATAACATCTA
3466 AAAGTGCAGCGGGTTACGAAGATTTTTTAAAAAACTTGACAGTTC
3511 ATTATTTGTACCGCCCTATTGTTACCTTTATGAATCACCTATGC

40 3556 AAGGGGCACAGACTGCATCTGGTATTATTTTAGCGCTTAATCGTA
3601 TAAGAAAATCGAATATAGACTATGATGTTGTTGTTATTGCTCGTG
3646 GCGGTGGTGCAAGAAGCGATCTGATGTATTTTGATGATTGTGCAC
3691 TTGGAATAGAAATTGCAAAGTTTAATGAGTATTGTCCAATTTTAT
3736 CGGGCATAGGTCATGAAAGAGATTTTACAATTCCAGATTATGTTG

45 3781 CCTGGAAGAGATTTGCTACTCCGACAGAAGTTGCAAGAGCTATAT
3826 CAAAGCAAATAGAAGATAATGTGAAAAAATTGGATGATAGTTATA

3871 ATGACTTAAGGATTTTACTTTCTAATGTTTTTAAAATCTATGAGA
 3916 GAACGGTAGAATTGGGTCTGATAGATTATATGAAGAAAGTTATAG
 3961 GAAGCGATTTTATAAAGATAGTAAAAGATCTGGATGAAACTTATG
 4006 AAAAGATTGAAAATTTTGTAGTTACAAAATAAATGATTCATCTC
 5 4051 AGAGACTATCTGAAGATTTTAAAGGTTTATGTCTAATTCTCTTG
 4096 AAAATAAGTTGAAATCCAAAAGGACAGTGTTGAAAATTTTGAAA
 4141 AAATACTTGAAAAAGATATATCAATTTTACTTTCAAATAAAGAGA
 4186 CAATGCTTAATGAAACATTTTCAGGAGCTTTTAAAACGAGAAGAAT
 4231 TTGCACCACTTTTATTTGGTGGGGCATTGGTTATGAAAAGTGGAC
 10 4276 ATTTTGTA AAA

The above nucleotide sequence was identified by a "degenerate primer" method that has broad utility and is an important aspect of the present invention. In the degenerate primer method, DNA fragments of any thermostable polymerase coding sequence corresponding to conserved domains of known thermostable DNA polymerases can be identified.

The degenerate primer method was developed by comparing the amino acid sequences of DNA polymerase I proteins from Taq, Tth, T7, and E. coli in which various conserved regions were identified. Primers corresponding to these conserved regions were then designed. As a result of the present invention, Taf sequences can be used to design other degenerate primers, as can the coding sequences of the Thermus species sps17 DNA polymerase I gene (see PCT Publication No. _____, filed September 30, 1991, and incorporated herein by reference) and the Thermotoga maritima DNA polymerase I gene (see PCT Publication No. _____, filed August 13, 1991, and incorporated herein by reference), and the Thermus species Z05 DNA polymerase I gene (see PCT Publication No. _____, filed September 30, 1991, and incorporated herein by reference). The generic utility of the degenerate primer process is exemplified herein by specific reference to the method as applied to cloning the Taf DNA polymerase I gene.

To clone the Taf DNA polymerase I gene, regions of conserved amino acid sequences of DNA polymerase I enzymes were converted to all of the possible codons which represent each of the amino acids. Due to the degenerate nature of the genetic code, a given amino acid may be represented by several different codons. Where more than one base can be present in a codon for a given amino acid, the sequence is said to be degenerate.

The primers were then synthesized as a pool of all of the possible DNA sequences that could code for a given amino acid sequence. The amount of degeneracy

of a given primer pool can be determined by multiplying the number of possible nucleotides at each position.

5 The greater the number of individual unique primer DNA sequences within a primer pool, the greater the probability that one of the unique primer sequences will bind to regions of the target chromosomal DNA other than the one desired; hence, the lesser the specificity of the resulting amplification. To increase the specificity of the amplification using degenerate primers, the pools are synthesized as subsets such that the entire group of subsets includes all possible DNA sequences encoding the given amino acid sequence, but each individual subset only includes a portion: for example, 10 one pool may contain either a G or C at a certain position while another pool contains either an A or T at the same position. As described herein, these subpools are designated with a DG number (where number is between 99 and 200).

Both forward primers (directed from the 5' region toward the 3' region of the gene, complementary to the noncoding strand) and reverse primers (directed from the 15 3' region of the gene toward the 5' region of the gene, complementary to the coding strand) were designed for most of the conserved regions to clone Taf polymerase. The primers were designed with restriction sites at the 5' ends of the primers to facilitate cloning. The forward primers contained a BglII restriction site (AGATCT), while the reverse primers contained an EcoRI restriction site (GAATTC). In addition, the 20 primers contained 2 additional nucleotides at the 5' end to increase the efficiency of cutting at the restriction site.

Degenerate primers were then used in PCR processes to amplify chromosomal DNA from Taf. The products of the PCR processes using a combination of forward and reverse primer pools in conjunction with a series of temperature profiles were 25 compared. When specific products of similar size to the product generated using Taq chromosomal DNA were produced, the PCR fragments were gel purified, reamplified and cloned into the vector pBSM13+HindIII::BglII (a derivative of the Stratagene™ vector pBSM13+, now marketed as pBS+, in which the HindIII site of pBSM13+ was converted to a BglII site). The PCR fragments were cloned and sequenced; fragments 30 were identified as potential thermostable DNA polymerase coding sequences if the fragments contained sequences that encode regions of amino acid homology to other known polymerase protein sequences, particularly those of Taq polymerase and Tth polymerase.

The portions of the Taf DNA polymerase gene were then identified in the 35 chromosomal DNA of Taf by Southern blot analysis. The Taf chromosomal DNA was digested with a variety of enzymes and transferred to nitrocellulose filters. Probes labeled with ³²P or biotin-dUTP were generated for various regions of the gene from

the cloned PCR products. The probes were hybridized to the nitrocellulose-bound genomic DNA, allowing identification of the molecular weight of the chromosomal DNA fragment hybridizing to the probe. The use of probes covering the 5' and 3' regions of the gene ensures that the DNA fragment(s) contain most if not all of the structural gene for the polymerase. Restriction enzymes can be identified that can be used to produce fragments that contain the structural gene in a single DNA fragment or in several DNA fragments to facilitate cloning.

Once identified, chromosomal DNA encoding portions of the Taf DNA polymerase gene was cloned. Chromosomal DNA was digested with the identified restriction enzymes, and size fractionated. Fractions containing the desired size range were concentrated, desalted, and cloned into the pBSM13+HindIII::BglII cloning vector. Clones were identified by hybridization using labeled probes generated from the previous cloned PCR products. The cloned fragments were identified by restriction enzyme analysis and Southern blot analysis.

The DNA sequence and amino acid sequence shown above and the DNA compounds that encode those sequences can be used to design and construct recombinant DNA expression vectors to express Taf DNA polymerase activity in a wide variety of host cells. A DNA compound encoding all or part of the DNA sequence shown above can also be used as a probe to identify thermostable polymerase-encoding DNA from other organisms, and the amino acid sequence shown above can be used to design peptides for use as immunogens to prepare antibodies that can be used to identify and purify a thermostable polymerase.

Whether produced by recombinant vectors that encode the above amino acid sequence or by native Taf cells, however, Taf DNA polymerase will typically be purified prior to use in a recombinant DNA technique. The present invention provides such purification methodology.

For recovering the native protein, the cells are grown using the method of Huber et al., 1989, System App. Microbial. 12:32-37. After cell growth, the isolation and purification of the enzyme takes place in six stages, each of which is carried out at a temperature below room temperature, preferably about 0° to about 4°C, unless stated otherwise.

In the first stage or step, the cells, if frozen, are thawed, disintegrated by ultrasound, suspended in a buffer at about pH 7.5, and centrifuged.

In the second stage, the supernatant is collected and then fractionated by adding a salt such as dry ammonium sulfate. The appropriate fraction (typically 45-75% of saturation) is collected, dissolved in a 0.2 M potassium phosphate buffer preferably at pH 6.5, and dialyzed against the same buffer.

The third step removes nucleic acids and some protein. The fraction from the second stage is applied to a DEAE-cellulose column equilibrated with the same buffer as used above. Then the column is washed with the same buffer and the flow-through protein-containing fractions, determined by absorbance at 280 nm, are collected and dialyzed against a 10 mM potassium phosphate buffer, preferably with the same ingredients as the first buffer, but at a pH of 7.5.

The fourth step consists of hydroxyapatite chromatography; the fraction so collected is applied to a hydroxyapatite column equilibrated with the buffer used for dialysis in the third step. The column is then washed and the enzyme eluted with a linear gradient of a buffer such as 0.01 M to 0.5 M potassium phosphate buffer at pH 7.5 containing 10 mM 2-mercaptoethanol and 5% glycerol. The pooled fractions containing thermostable DNA polymerase activity are dialyzed against the same buffer used for dialysis in the third step.

The fifth stage consists of anion exchange chromatography; the dialyzed fraction is applied to a DEAE-cellulose column, equilibrated with the buffer used for dialysis in the third step. The column is then washed and the enzyme eluted with a linear gradient of a buffer such as 0.01 to 0.6 M KCl in the buffer used for dialysis in the third step. Fractions with thermostable enzyme activity are then tested for contaminating deoxyribonucleases (endo- and exonucleases) using any suitable procedure. For example, the endonuclease activity may be determined electrophoretically from the change in molecular weight of phage lambda DNA or supercoiled plasmid DNA after incubation with an excess of DNA polymerase. Similarly, exonuclease activity may be determined electrophoretically from the change in molecular weight of restriction enzyme-cleaved DNA after treatment with the DNA polymerase fraction. The fractions determined to have polymerase activity but no deoxyribonuclease activity are pooled and dialyzed against the same buffer used in the third step.

The sixth step consists of DNA binding protein affinity chromatography; the pooled fractions are placed on a phosphocellulose column with a set bed volume. The column is washed and the enzyme eluted with a linear gradient of a buffer such as 0.01 to 0.8 M KCl in a potassium phosphate buffer at pH 7.5. The pooled fractions having thermostable polymerase activity and no deoxyribonuclease activity are dialyzed against a buffer at pH 8.0.

The molecular weight of the DNA polymerase purified from Taf may be determined by any technique, for example, by SDS-PAGE analysis using protein molecular weight markers. The molecular weight, calculated from the coding sequence, of Taf DNA polymerase I is 103,273 daltons. The purification protocol of

native Taf DNA polymerase is described in detail in Example 1. Purification of the recombinant Taf polymerase of the invention can be carried out with similar methodology.

5 The entire coding sequence of the Taf DNA polymerase gene is not required, however, to produce a biologically active gene product with DNA polymerase activity. The availability of DNA encoding the Taf DNA polymerase sequence provides the opportunity to modify the coding sequence so as to generate mutein (mutant protein) forms also having DNA polymerase activity. The amino(N)-terminal portion of the Taf polymerase is not believed to be necessary for polymerase activity. Using recombinant
10 DNA methodology, one can delete up to approximately one-third of the N-terminal coding sequence of the Taf gene, clone, and express a gene product that is quite active in polymerase assays. Because certain N-terminal shortened forms of the polymerase are active, the gene constructs used for expression of these polymerases can include the corresponding shortened forms of the coding sequence.

15 In addition to the N-terminal deletions, individual amino acid residues in the peptide chain of Taf polymerase may be modified by oxidation, reduction, or other derivation, and the protein may be cleaved to obtain fragments that retain activity. Such alterations that do not destroy activity do not remove the protein from the definition of a protein with Taf polymerase activity and so are specifically included within the scope of
20 the present invention.

Modifications to the primary structure of the Taf DNA polymerase gene by deletion, addition, or alteration so as to change the amino acids incorporated into the Taf DNA polymerase during translation can be made without destroying the high temperature DNA polymerase activity of the protein. Such substitutions or other
25 alterations result in the production of proteins having an amino acid sequence encoded by DNA falling within the contemplated scope of the present invention. Likewise, the cloned genomic sequence, or homologous synthetic sequences, of the Taf DNA polymerase gene can be used to express a fusion polypeptide with Taf DNA polymerase activity or to express a protein with an amino acid sequence identical to that
30 of native Taf DNA polymerase. In addition, such expression can be directed by a control sequence that functions in whatever host is chosen to express the Taf DNA polymerase.

Thus, the present invention provides a coding sequence for Taf DNA polymerase from which expression vectors applicable to a variety of host systems can
35 be constructed and the coding sequence expressed. Portions of the Taf polymerase-encoding sequence are also useful as probes to retrieve other thermostable polymerase-encoding sequences in a variety of species. Accordingly, oligonucleotide probes that

encode at least four to six amino acids can be synthesized and used to retrieve additional DNAs encoding a thermostable polymerase. Because there may not be an exact match between the nucleotide sequence of the thermostable DNA polymerase gene of Taf and the corresponding gene of other species, oligomers containing approximately 12-18 nucleotides (encoding the four to six amino sequence) are usually necessary to obtain hybridization under conditions of sufficient stringency to eliminate false positives. Sequences encoding six amino acids supply ample information for such probes.

The present invention, by providing coding sequences and amino acid sequences for Taf DNA polymerase, therefore enables the isolation of other thermostable polymerase enzymes and the coding sequences for those enzymes. The deduced amino acid sequence of the Taf DNA polymerase I protein is similar to the amino acid sequences for other thermostable DNA polymerases, such as those from Taq and Tth (see PCT Publication No. 91/09950, incorporated herein by reference).

However, regions of dissimilarity between the coding sequences of the thermostable DNA polymerases can also be used as probes to identify other thermostable polymerase coding sequences which encode enzymes having some properties of one known thermostable polymerase and perhaps different properties. For example, the coding sequence for a thermostable polymerase having some properties of Taq and other divergent properties of Taf may be identified by using probes comprising regions of dissimilarity between Taq and Taf.

Whether one desires to produce an enzyme identical to native Taf DNA polymerase or a derivative or homologue of that enzyme, the production of a recombinant form of Taf polymerase typically involves the construction of an expression vector, the transformation of a host cell with the vector, and culture of the transformed host cell under conditions such that expression will occur.

To construct the expression vector, a DNA is obtained that encodes the mature (used here to include all muteins) enzyme or a fusion of the Taf polymerase to an additional sequence that does not destroy activity or to an additional sequence cleavable under controlled conditions (such as treatment with peptidase) to give an active protein. The coding sequence is then placed in operable linkage with suitable control sequences in an expression vector. The vector can be designed to replicate autonomously in the host cell or to integrate into the chromosomal DNA of the host cell. The vector is used to transform a suitable host, and the transformed host is cultured under conditions suitable for expression of recombinant Taf polymerase. The Taf polymerase is isolated from the medium or from the cells, although recovery and purification of the protein may not be necessary in some instances.

Each of the foregoing steps can be done in a variety of ways. For example, the desired coding sequence may be obtained from genomic fragments and used directly in appropriate hosts. The construction of expression vectors operable in a variety of hosts is made using appropriate replicons and control sequences, as set forth generally below. Construction of suitable vectors containing the desired coding and control sequences employs standard ligation and restriction techniques that are well understood in the art. Isolated plasmids, DNA sequences, or synthesized oligonucleotides are cleaved, modified, and religated in the form desired. Suitable restriction sites can, if not normally available, be added to the ends of the coding sequence so as to facilitate construction of an expression vector, as exemplified below.

Site-specific DNA cleavage is performed by treating with the suitable restriction enzyme (or enzymes) under conditions that are generally understood in the art and specified by the manufacturers of commercially available restriction enzymes. See, e.g., New England Biolabs, Product Catalog. In general, about 1 μ g of plasmid or other DNA is cleaved by one unit of enzyme in about 20 μ l of buffer solution; in the examples below, an excess of restriction enzyme is generally used to ensure complete digestion of the DNA. Incubation times of about one to two hours at about 37°C are typical, although variations can be tolerated. After each incubation, protein is removed by extraction with phenol and chloroform; this extraction can be followed by ether extraction and recovery of the DNA from aqueous fractions by precipitation with ethanol. If desired, size separation of the cleaved fragments may be performed by polyacrylamide gel or agarose gel electrophoresis using standard techniques. See, e.g., Maxam et al., *Methods in Enzymology*, 1980, 65:499-560.

Restriction-cleaved fragments with single-strand "overhanging" termini can be made blunt-ended (double-strand ends) by treating with the large fragment of *E. coli* DNA polymerase I (Klenow) in the presence of the four deoxynucleoside triphosphates (dNTPs) using incubation times of about 15 to 25 minutes at 20°C to 25°C in 50 mM Tris, pH 7.6, 50 mM NaCl, 10 mM MgCl₂, 10 mM DTT, and 5 to 10 μ M dNTPs. The Klenow fragment fills in at 5' protruding ends, but chews back protruding 3' single strands, even though the four dNTPs are present. If desired, selective repair can be performed by supplying only one of the, or selected, dNTPs within the limitations dictated by the nature of the protruding ends. After treatment with Klenow, the mixture is extracted with phenol/chloroform and ethanol precipitated. Similar results can be achieved using S1 nuclease, because treatment under appropriate conditions with S1 nuclease results in hydrolysis of any single-stranded portion of a nucleic acid.

Synthetic oligonucleotides can be prepared using the triester method of Matteucci et al., 1981, *J. Am. Chem. Soc.* 103:3185-3191, or automated synthesis

methods. Kinasing of single strands prior to annealing or for labeling is achieved using an excess, e.g., approximately 10 units, of polynucleotide kinase to 0.5 μ M substrate in the presence of 50 mM Tris, pH 7.6, 10 mM $MgCl_2$, 5 mM dithiothreitol (DTT), and 1 to 2 μ M ATP. If kinasing is for labeling of probe, the ATP will be labeled with ^{32}P .

5 Ligations are performed in 15-30 μ l volumes under the following standard conditions and temperatures: 20 mM Tris-Cl, pH 7.5, 10 mM $MgCl_2$, 10 mM DTT, 33 μ g/ml BSA, 10 mM-50 mM NaCl, and either 40 μ M ATP and 0.01-0.02 (Weiss) units T4 DNA ligase at 0°C (for ligation of fragments with complementary single-stranded ends) or 1 mM ATP and 0.3-0.6 units T4 DNA ligase at 14°C (for "blunt end" 10 ligation). Intermolecular ligations of fragments with complementary ends are usually performed at 33-100 μ g/ml total DNA concentrations (5-100 nM total ends concentration). Intermolecular blunt end ligations (usually employing a 20-30 fold molar excess of linkers, optionally) are performed at 1 μ M total ends concentration.

15 In vector construction, the vector fragment is commonly treated with bacterial or calf intestinal alkaline phosphatase (BAP or CIAP) to remove the 5' phosphate and prevent religation and reconstruction of the vector. BAP and CIAP digestion conditions are well known in the art, and published protocols usually accompany the commercially available BAP and CIAP enzymes. To recover the nucleic acid fragments, the preparation is extracted with phenol-chloroform and ethanol precipitated 20 to remove the phosphatase and purify the DNA. Alternatively, religation of unwanted vector fragments can be prevented by restriction enzyme digestion before or after ligation, if appropriate restriction sites are available.

25 For portions of vectors or coding sequences that require sequence modifications, a variety of site-specific primer-directed mutagenesis methods are available. The polymerase chain reaction (PCR) can be used to perform site-specific mutagenesis. In another technique now standard in the art, a synthetic oligonucleotide encoding the desired mutation is used as a primer to direct synthesis of a complementary nucleic acid sequence contained in of a single-stranded vector, such as pBSM13+ derivatives, that serves as a template for construction of the extension 30 product of the mutagenizing primer. The mutagenized DNA is transformed into a host bacterium, and cultures of the transformed bacteria are plated and identified. The identification of modified vectors may involve transfer of the DNA of selected transformants to a nitrocellulose filter or other membrane and the "lifts" hybridized with kinased synthetic mutagenic primer at a temperature that permits hybridization of an exact match to the modified sequence but prevents hybridization with the original 35 unmutagenized strand. Transformants that contain DNA that hybridizes with the probe

are then cultured (the sequence of the DNA is generally confirmed by sequence analysis) and serve as a reservoir of the modified DNA.

In the construction set forth below, correct ligations for plasmid construction are confirmed by first transforming E. coli strain DG101 (ATCC 47043) or another
5 suitable host with the ligation mixture. Successful transformants are selected by ampicillin, tetracycline or other antibiotic resistance or sensitivity or by using other markers, depending on the mode of plasmid construction, as is understood in the art. Plasmids from the transformants are then prepared according to the method of Clewell et al., 1969, Proc. Natl. Acad. Sci. USA 62:1159, optionally following
10 chloramphenicol-amplification (Clewell, 1972, J. Bacteriol. 110:667). Another method for obtaining plasmid DNA is described as the "Base-Acid" extraction method at page 11 of the Bethesda Research Laboratories publication Focus, volume 5, number 2, and very pure plasmid DNA can be obtained by replacing steps 12 through 17 of the protocol with CsCl/ethidium bromide ultracentrifugation of the DNA. The isolated
15 DNA is analyzed by restriction enzyme digestion and/or sequenced by the dideoxy method of Sanger et al., 1977, Proc. Natl. Acad. Sci. USA 74:5463, as further described by Messing et al., 1981, Nuc. Acids Res. 9:309, or by the method of Maxam et al., 1980, Methods in Enzymology 65:499.

The control sequences, expression vectors, and transformation methods are
20 dependent on the type of host cell used to express the gene. Generally, procaryotic, yeast, insect, or mammalian cells are used as hosts. Procaryotic hosts are in general the most efficient and convenient for the production of recombinant proteins and are therefore preferred for the expression of Taf polymerase.

The procaryote most frequently used to express recombinant proteins is E. coli.
25 For cloning and sequencing, and for expression of constructions under control of most bacterial promoters, E. coli K12 strain MM294, obtained from the E. coli Genetic Stock Center under GCSC #6135, can be used as the host. For expression vectors with the $P_{LN_{RBS}}$ or $P_{LT_{RBS}}$ control sequence, E. coli K12 strain MC1000 lambda lysogen, $\lambda N_7N_{53}CI857$ $SusP_{80}$, ATCC 39531, may be used. E. coli DG116, which
30 was deposited with the ATCC (ATCC 53606) on April 7, 1987, and E. coli KB2, which was deposited with the ATCC (ATCC 53075) on March 29, 1985, are also useful host cells. For M13 phage recombinants, E. coli strains susceptible to phage infection, such as E. coli K12 strain DG98, are employed. The DG98 strain was deposited with the ATCC (ATCC 39768) on July 13, 1984.

35 However, microbial strains other than E. coli can also be used, such as bacilli, for example Bacillus subtilis, various species of Pseudomonas, and other bacterial strains, for recombinant expression of Taf DNA polymerase. In such procaryotic

systems, plasmid vectors that contain replication sites and control sequences derived from the host or a species compatible with the host are typically used.

For example, *E. coli* is typically transformed using derivatives of pBR322, described by Bolivar *et al.*, 1977, *Gene* 2:95. Plasmid pBR322 contains genes for ampicillin and tetracycline resistance. These drug resistance markers can be either retained or destroyed in constructing the desired vector and so help to detect the presence of a desired recombinant. Commonly used procaryotic control sequences, i.e., a promoter for transcription initiation, optionally with an operator, along with a ribosome binding site sequence, include the β -lactamase (penicillinase) and lactose (*lac*) promoter systems (Chang *et al.*, 1977, *Nature* 198:1056), the tryptophan (*trp*) promoter system (Goeddel *et al.*, 1980, *Nuc. Acids Res.* 8:4057), and the lambda-derived P_L promoter (Shimatake *et al.*, 1981, *Nature* 292:128) and N-gene ribosome binding site (N_{RBS}). A portable control system cassette is set forth in United States Patent No. 4,711,845, issued December 8, 1987. This cassette comprises a P_L promoter operably linked to the N_{RBS} in turn positioned upstream of a third DNA sequence having at least one restriction site that permits cleavage within six bp 3' of the N_{RBS} sequence. Also useful is the phosphatase A (*phoA*) system described by Chang *et al.* in European Patent Publication No. 196,864, published October 8, 1986. However, any available promoter system compatible with procaryotes can be used to construct a *Taf* expression vector of the invention.

In addition to bacteria, eucaryotic microbes, such as yeast, can also be used as recombinant host cells. Laboratory strains of *Saccharomyces cerevisiae*, Baker's yeast, are most often used, although a number of other strains are commonly available. While vectors employing the two micron origin of replication are common (Broach, 1983, *Meth. Enz.* 101:307), other plasmid vectors suitable for yeast expression are known (see, for example, Stinchcomb *et al.*, 1979, *Nature* 282:39; Tschempe *et al.*, 1980, *Gene* 10:157; and Clarke *et al.*, 1983, *Meth. Enz.* 101:300). Control sequences for yeast vectors include promoters for the synthesis of glycolytic enzymes (Hess *et al.*, 1968, *J. Adv. Enzyme Reg.* 7:149; Holland *et al.*, 1978, *Biotechnology* 17:4900; and Holland *et al.*, 1981, *J. Biol. Chem.* 256:1385). Additional promoters known in the art include the promoter for 3-phosphoglycerate kinase (Hitzeman *et al.*, 1980, *J. Biol. Chem.* 255:2073) and those for other glycolytic enzymes, such as glyceraldehyde 3-phosphate dehydrogenase, hexokinase, pyruvate decarboxylase, phosphofructokinase, glucose-6-phosphate isomerase, 3-phosphoglycerate mutase, pyruvate kinase, triosephosphate isomerase, phosphoglucose isomerase, and glucokinase. Other promoters that have the additional advantage of transcription controlled by growth conditions are the promoter regions for alcohol dehydrogenase 2, isocytochrome C,

acid phosphatase, degradative enzymes associated with nitrogen metabolism, and enzymes responsible for maltose and galactose utilization (Holland, *supra*).

Terminator sequences may also be used to enhance expression when placed at the 3' end of the coding sequence. Such terminators are found in the 3' untranslated region following the coding sequences in yeast-derived genes. Any vector containing a yeast-compatible promoter, origin of replication, and other control sequences is suitable for use in constructing yeast Taf expression vectors.

The Taf gene can also be expressed in eucaryotic host cell cultures derived from multicellular organisms. See, for example, Tissue Culture, Academic Press, Cruz and Patterson, editors (1973). Useful host cell lines include COS-7, COS-A2, CV-1, murine cells such as murine myelomas N51 and VERO, HeLa cells, and Chinese hamster ovary (CHO) cells. Expression vectors for such cells ordinarily include promoters and control sequences compatible with mammalian cells such as, for example, the commonly used early and late promoters from Simian Virus 40 (SV 40) (Fiers *et al.*, 1978, Nature 273:113), or other viral promoters such as those derived from polyoma, adenovirus 2, bovine papilloma virus (BPV), or avian sarcoma viruses, or immunoglobulin promoters and heat shock promoters. A system for expressing DNA in mammalian systems using a BPV vector system is disclosed in United States Patent No. 4,419,446. A modification of this system is described in United States Patent No. 4,601,978. General aspects of mammalian cell host system transformations have been described by Axel, United States Patent No. 4,399,216. "Enhancer" regions are also important in optimizing expression; these are, generally, sequences found upstream of the promoter region. Origins of replication may be obtained, if needed, from viral sources. However, integration into the chromosome is a common mechanism for DNA replication in eucaryotes.

Plant cells can also be used as hosts, and control sequences compatible with plant cells, such as the nopaline synthase promoter and polyadenylation signal sequences (Depicker *et al.*, 1982, J. Mol. Appl. Gen. 1:561) are available. Expression systems employing insect cells utilizing the control systems provided by baculovirus vectors have also been described (Miller *et al.*, in Genetic Engineering (1986), Setlow *et al.*, eds., Plenum Publishing, Vol. 8, pp. 277-297). Insect cell-based expression can be accomplished in Spodoptera frugiperda. These systems are also successful in producing recombinant Taf polymerase.

Depending on the host cell used, transformation is done using standard techniques appropriate to such cells. The calcium treatment employing calcium chloride, as described by Cohen, 1972, Proc. Natl. Acad. Sci. USA 69:2110 is used for procaryotes or other cells that contain substantial cell wall barriers. Infection with

Agrobacterium tumefaciens (Shaw et al., 1983, Gene 23:315) is used for certain plant cells. For mammalian cells, the calcium phosphate precipitation method of Graham and van der Eb, 1978, Virology 52:546 is preferred. Transformations into yeast are carried out according to the method of Van Solingen et al., 1977, J. Bact. 130:946, and Hsiao et al., 1979, Proc. Natl. Acad. Sci. USA 76:3829.

Once the Taf DNA polymerase has been expressed in a recombinant host cell, purification of the protein may be desired. Although a variety of purification procedures can be used to purify the recombinant thermostable polymerase of the invention, fewer steps may be necessary to yield an enzyme preparation of equal purity. Because E. coli host proteins are heat-sensitive, the recombinant thermostable Taf DNA polymerase can be substantially enriched by heat inactivating the crude lysate. This step is done in the presence of a sufficient amount of salt (typically 0.3 M ammonium sulfate) to ensure dissociation of the Taf DNA polymerase from the host DNA and to reduce ionic interactions of Taf DNA polymerase with other cell lysate proteins.

In addition, the presence of 0.3 M ammonium sulfate promotes hydrophobic interaction with a phenyl sepharose column. Hydrophobic interaction chromatography is a separation technique in which substances are separated on the basis of differing strengths of hydrophobic interaction with an uncharged bed material containing hydrophobic groups. Typically, the column is first equilibrated under conditions favorable to hydrophobic binding, such as high ionic strength. A descending salt gradient may then be used to elute the sample.

According to the invention, an aqueous mixture (containing either native or recombinant Taf DNA polymerase) is loaded onto a column containing a relatively strong hydrophobic gel such as phenyl sepharose (manufactured by Pharmacia) or Phenyl TSK (manufactured by Toyo Soda). To promote hydrophobic interaction with a phenyl sepharose column, a solvent is used which contains, for example, greater than or equal to 0.3 M ammonium sulfate. The column and the sample are adjusted to 0.3 M ammonium sulfate in 50 mM Tris (pH 7.5) and 5 mM EDTA ("TE") buffer that also contains 0.5 mM DTT, and the sample is applied to the column. The column is washed with the 0.3 M ammonium sulfate buffer. The enzyme may then be eluted with solvents which attenuate hydrophobic interactions, such as decreasing salt gradients, or increasing gradients or addition of ethylene or propylene glycol, or urea. For native Taf DNA polymerase, a preferred embodiment involves washing the column with 2 M urea in 20% ethylene glycol in TE-DTT wash.

For long-term stability, Taf DNA polymerase enzyme can be stored in a buffer that contains one or more non-ionic polymeric detergents. Such detergents are generally those that have a molecular weight in the range of approximately 100 to

250,000 daltons, preferably about 4,000 to 200,000 daltons and stabilize the enzyme at a pH of from about 3.5 to about 9.5, preferably from about 4 to 8.5. Examples of such detergents include those specified on pages 295-298 of McCutcheon's Emulsifiers & Detergents, North American edition (1983), published by the McCutcheon Division of
5 MC Publishing Co., 175 Rock Road, Glen Rock, NJ (USA).

Preferably, the detergents are selected from the group comprising ethoxylated fatty alcohol ethers and lauryl ethers, ethoxylated alkyl phenols, octylphenoxy polyethoxy ethanol compounds, modified oxyethylated and/or oxypropylated straight-chain alcohols, polyethylene glycol monooleate compounds, polysorbate compounds,
10 and phenolic fatty alcohol ethers. More particularly preferred are Tween 20, a polyoxyethylated (20) sorbitan monolaurate from ICI Americas Inc., Wilmington, D.E., and Iconol NP-40, an ethoxylated alkyl phenol (nonyl) from BASF Wyandotte Corp. Parsippany, NJ.

The thermostable enzyme of this invention may be used for any purpose in
15 which such enzyme activity is necessary or desired. In a particularly preferred embodiment, the enzyme catalyzes the nucleic acid amplification reaction known as PCR. The process for amplifying nucleic acid sequences is disclosed and claimed in United States Patent No. 4,683,202, issued July 28, 1987, the disclosure of which is incorporated herein by reference. The PCR nucleic acid amplification method involves
20 amplifying at least one specific nucleic acid sequence contained in a nucleic acid or a mixture of nucleic acids and in the most common embodiment, produces double-stranded DNA.

For ease of discussion, the protocol set forth below assumes that the specific sequence to be amplified is contained in a double-stranded nucleic acid. However, the
25 process is equally useful in amplifying single-stranded nucleic acid, such as mRNA, although in the preferred embodiment the ultimate product is still double-stranded DNA. In the amplification of a single-stranded nucleic acid, the first step involves the synthesis of a complementary strand (one of the two amplification primers can be used for this purpose), and the succeeding steps proceed as in the double-stranded
30 amplification process described below.

This amplification process comprises the steps of:

(a) contacting each nucleic acid strand with four different nucleoside triphosphates and one oligonucleotide primer for each strand of the specific sequence being amplified, wherein each primer is selected to be substantially complementary to
35 the different strands of the specific sequence, such that the extension product synthesized from one primer, when it is separated from its complement, can serve as a template for synthesis of the extension product of the other primer, said contacting

being at a temperature which allows hybridization of each primer to a complementary nucleic acid strand;

(b) contacting each nucleic acid strand; at the same time as or after step (a), with a DNA polymerase from Taf which enables combination of the nucleoside triphosphates to form primer extension products complementary to each strand of the specific nucleic acid sequence;

(c) maintaining the mixture from step (b) at an effective temperature for an effective time to promote the activity of the enzyme and to synthesize, for each different sequence being amplified, an extension product of each primer which is complementary to each nucleic acid strand template, but not so high as to separate each extension product from the complementary strand template;

(d) heating the mixture from step (c) for an effective time and at an effective temperature to separate the primer extension products from the templates on which they were synthesized to produce single-stranded molecules but not so high as to denature irreversibly the enzyme;

(e) cooling the mixture from step (d) for an effective time and to an effective temperature to promote hybridization of a primer to each of the single-stranded molecules produced in step (d); and

(f) maintaining the mixture from step (e) at an effective temperature for an effective time to promote the activity of the enzyme and to synthesize, for each different sequence being amplified, an extension product of each primer which is complementary to each nucleic acid template produced in step (d) but not so high as to separate each extension product from the complementary strand template. The effective times and temperatures in steps (e) and (f) may coincide, so that steps (e) and (f) can be carried out simultaneously. Steps (d)-(f) are repeated until the desired level of amplification is obtained.

The amplification method is useful not only for producing large amounts of a specific nucleic acid sequence of known sequence but also for producing nucleic acid sequences which are known to exist but are not completely specified. One need know only a sufficient number of bases at both ends of the sequence in sufficient detail so that two oligonucleotide primers can be prepared which will hybridize to different strands of the desired sequence at relative positions along the sequence such that an extension product synthesized from one primer, when separated from the template (complement), can serve as a template for extension of the other primer. The greater the knowledge about the bases at both ends of the sequence, the greater can be the specificity of the primers for the target nucleic acid sequence.

In any case, an initial copy of the sequence to be amplified must be available, although the sequence need not be pure or a discrete molecule. In general, the amplification process involves a chain reaction for producing at least one specific nucleic acid sequence, called the "target" sequence, given that (a) the ends of the target sequence are known in sufficient detail that oligonucleotides can be synthesized which will hybridize to them, and (b) a small amount of the sequence is available to initiate the chain reaction. The product accumulates exponentially relative to the number of reaction steps involved. The product of the chain reaction is a discrete nucleic duplex with termini corresponding to the ends of the specific primers employed.

Any nucleic acid sequence, in purified or nonpurified form, can be utilized as the starting nucleic acid(s), provided it contains or is suspected to contain the specific nucleic acid sequence desired. The nucleic acid to be amplified can be obtained from any source, for example, from plasmids such as pBR322, from cloned DNA or RNA, from natural DNA or RNA from any source, including bacteria, yeast, viruses, organelles, and higher organisms such as plants and animals, or from preparations of nucleic acid made in vitro. DNA or RNA may be extracted from blood, tissue material such as chorionic villi, or amniotic cells by a variety of techniques. See, e.g., Maniatis et al., 1982, Molecular Cloning: A Laboratory Manual (Cold Spring Harbor Laboratory, Cold Spring Harbor, New York) pp. 280-281. Thus, the process may employ, for example, DNA or RNA, including messenger RNA, which DNA or RNA may be single-stranded or double-stranded. In addition, a DNA-RNA hybrid which contains one strand of each may be utilized. A mixture of any of these nucleic acids can also be employed as can nucleic acids produced from a previous amplification reaction (using the same or different primers). The specific nucleic acid sequence to be amplified may be only a fraction of a large molecule or can be present initially as a discrete molecule, so that the specific sequence constitutes the entire nucleic acid.

The sequence to be amplified need not be present initially in a pure form; the sequence can be a minor fraction of a complex mixture, such as a portion of the β -globin gene contained in whole human DNA (as exemplified in Saiki et al., 1985, Science 230:1530-1534) or a portion of a nucleic acid sequence due to a particular microorganism, which organism might constitute only a very minor fraction of a particular biological sample. The cells can be directly used in the amplification process after suspension in hypotonic buffer and heat treatment at about 90°-100°C until cell lysis and dispersion of intracellular components occur (generally 1 to 15 minutes). After the heating step, the amplification reagents may be added directly to the lysed cells. The starting nucleic acid sequence may contain more than one desired specific nucleic acid sequence. The amplification process is useful not only for producing large

amounts of one specific nucleic acid sequence but also for amplifying simultaneously more than one different specific nucleic acid sequence located on the same or different nucleic acid molecules.

Primers play a key role in the PCR process. The word "primer" as used in
5 describing the amplification process can refer to more than one primer, particularly in the case where there is some ambiguity in the information regarding the terminal sequence(s) of the fragment to be amplified. For instance, in the case where a nucleic acid sequence is inferred from protein sequence information, a collection of primers containing sequences representing all possible codon variations based on degeneracy of
10 the genetic code will be used for each strand. A least one primer from this collection will be sufficiently homologous with the end of the desired sequence to be amplified to be useful for amplification.

In addition, more than one specific nucleic acid sequence can be amplified from the first nucleic acid or mixture of nucleic acids, so long as the appropriate number of
15 different oligonucleotide primers are utilized. For example, if two different specific nucleic acid sequences are to be produced, four primers are utilized. Two of the primers are specific for one of the specific nucleic acid sequences and the other two primers are specific for the second specific nucleic acid sequence. In this manner, each of the two different specific sequences can be produced exponentially by the present
20 process. When allelic variants or different members of a multigene family are to be amplified, however, one can often amplify several different sequences with a single set of primers.

A sequence within a given sequence can be amplified after a given number of amplifications to obtain greater specificity of the reaction by adding after at least one
25 cycle of amplification a set of primers that are complementary to internal sequences (that are not on the ends) of the sequence to be amplified. Such primers may be added at any stage and will provide a shorter amplified fragment. Alternatively, a longer fragment can be prepared by using primers with non-complementary 5' ends but having some 3' overlap with the 5' ends of the primers previously utilized in the amplification.

30 Primers also play a key role when the amplification process is used for in vitro mutagenesis. The product of an amplification reaction where the primers employed are not exactly complementary to the original template will contain the sequence of the primer rather than the template, so introducing an in vitro mutation. Although the initial cycles may be somewhat inefficient, due to the mismatch between the mutagenic primer and the target, in further cycles the mutation will be amplified with an undiminished
35 efficiency because no further mispaired priming is required. The process of making an altered DNA sequence as described above could be repeated on the altered DNA using

different primers to induce further sequence changes. In this way, a series of mutated sequences can gradually be produced wherein each new addition to the series differs from the last in a minor way, but from the original DNA source sequence in an increasingly major way.

5 Because the primer can contain as part of its sequence a non-complementary sequence, provided that a sufficient amount of the primer contains a sequence that is complementary to the strand to be amplified, many other advantages can be realized. For example, a nucleotide sequence that is not complementary to the template sequence (such as, e.g., a promoter, linker, coding sequence, etc.) may be attached at the 5' end
10 of one or both of the primers and so appended to the product of the amplification process. After the extension primer is added, sufficient cycles are run to achieve the desired amount of new template containing the non-complementary nucleotide insert. This allows production of large quantities of the combined fragments in a relatively short period of time (e.g., two hours or less) using a simple technique.

15 Oligonucleotide primers can be prepared using any suitable method, such as, for example, the phosphotriester and phosphodiester methods or automated embodiments thereof. The phosphotriester method is described in Narang *et al.*, 1979, Meth. Enzymol. 68:90, and U.S. Patent No. 4,356,270. The phosphodiester method is described in Brown *et al.*, 1979, Meth. Enzymol. 68:109. In one such automated
20 embodiment, diethylphosphoramidites are used as starting materials and may be synthesized as described by Beaucage *et al.*, 1981, Tetrahedron Letters 22:1859-1862. One method for synthesizing oligonucleotides on a modified solid support is described in United States Patent No. 4,458,066. One can also use a primer that has been isolated from a biological source (such as a restriction endonuclease digest).

25 To produce a specific nucleic acid sequence using PCR, a nucleic acid containing that sequence is used as a template. The first step involves contacting each nucleic acid strand with four different nucleoside triphosphates and one oligonucleotide primer for each strand of each specific nucleic acid sequence being amplified or detected. If the nucleic acids to be amplified or detected are DNA, then the nucleoside
30 triphosphates are usually dATP, dCTP, dGTP, and dTTP, although various nucleotide derivatives can also be used in the process. The concentration of nucleoside triphosphates can vary widely. Typically the concentration is 50-200 μ M of each dNTP in the buffer for amplification, and $MgCl_2$ is present in the buffer in an amount of 1 to 3 mM to activate the polymerase and increase the specificity of the reaction.
35 However, dNTP concentrations of 1-20 μ M may be preferred for some applications, such as DNA sequencing or labeling PCR products at high specific activity.

The nucleic acid strands of the target nucleic acid serve as templates for the synthesis of additional nucleic acid strands, which are extension products of the primers. This synthesis can be performed using any suitable method, but generally occurs in a buffered aqueous solution, preferably at a pH of 7 to 9, most preferably about 8. To facilitate synthesis, a molar excess of the two oligonucleotide primers is added to the buffer containing the template strands. As a practical matter, the amount of primer added will generally be in molar excess over the amount of complementary strand (template) when the sequence to be amplified is contained in a mixture of complicated long-chain nucleic acid strands. A large molar excess is preferred to improve the efficiency of the process. Accordingly, primer:template ratios of about 1000:1 are generally employed for cloned DNA templates, and primer: template ratios of about 10⁸:1 are generally employed for amplification from complex genomic samples.

The mixture of template, primers, and nucleoside triphosphates is then treated according to whether the nucleic acids being amplified or detected are double- or single-stranded. If the nucleic acids are single-stranded, then no denaturation step need be employed, and the reaction mixture is held at a temperature which promotes hybridization of the primer to its complementary target (template) sequence. Such temperature is generally from about 35°C to 65°C or more, preferably about 37-60°C for an effective time, generally from a few seconds to five minutes, preferably from 30 seconds to one minute. A hybridization temperature of 35-80°C may be used for Taf DNA polymerase, and 15-mer or longer primers are used to increase the specificity of primer hybridization. Shorter primers require lower hybridization temperatures or agents which stabilize double-stranded DNA.

The complement to the original single-stranded nucleic acids can be synthesized by adding Taf DNA polymerase in the presence of the appropriate buffer, dNTPs, and one or more oligonucleotide primers. If an appropriate single primer is added, the primer extension product will be complementary to the single-stranded nucleic acid and will be hybridized with the nucleic acid strand in a duplex of strands of equal or unequal length (depending where the primer hybridizes on the template), which may then be separated into single strands as described above to produce two single, separated, complementary strands. Alternatively, two or more appropriate primers (one of which will prime synthesis using the extension product of the other primer as a template) may be added to the single-stranded nucleic acid and the reaction carried out.

If the nucleic acid contains two strands, as in the case of amplification of a double-stranded target or second-cycle amplification of a single-stranded target, the strands of nucleic acid must be separated before the primers are hybridized. This strand

separation can be accomplished by any suitable denaturing method, including physical, chemical or enzymatic means. One preferred physical method of separating the strands of the nucleic acid involves heating the nucleic acid until complete (>99%) denaturation occurs. Typical heat denaturation involves temperatures ranging from about 90° to 105°C for times generally ranging from about a few seconds to 4 minutes, depending on the composition and size of the nucleic acid. Preferably, the effective denaturing temperature is 90°-100°C for a few seconds to 1 minute. Strand separation may also be induced by an enzyme from the class of enzymes known as helicases or the enzyme RecA, which has helicase activity and in the presence of ATP is known to denature DNA. The reaction conditions suitable for separating the strands of nucleic acids with helicases are described by Kuhn Hoffmann-Berling, 1978, CSH-Quantitative Biology 43:63, and techniques for using RecA are reviewed in Radding, 1982, Ann. Rev. Genetics 16:405-437. The denaturation produces two separated complementary strands of equal or unequal length.

If the double-stranded nucleic acid is denatured by heat, the reaction mixture is allowed to cool to a temperature which promotes hybridization of each primer to the complementary target (template) sequence. This temperature is usually from about 35°C to 65°C or more, depending on reagents, preferably 37°-60°C. The hybridization temperature is maintained for an effective time, generally 30 seconds to 5 minutes, and preferably 1-3 minutes. In practical terms, the temperature is simply lowered from about 95°C to as low as 37°C, and hybridization occurs at a temperature within this range.

Whether the nucleic acid is single- or double-stranded, the DNA polymerase from Taf may be added at the denaturation step or when the temperature is being reduced to or is in the range for promoting hybridization. Although the thermostability of Taf polymerase allows one to add Taf polymerase to the reaction mixture at any time, one can substantially inhibit non-specific amplification by adding the polymerase to the reaction mixture at a point in time when the mixture will not be cooled below the stringent hybridization temperature. After hybridization, the reaction mixture is then heated to or maintained at a temperature at which the activity of the enzyme is promoted or optimized, i.e., a temperature sufficient to increase the activity of the enzyme in facilitating synthesis of the primer extension products from the hybridized primer and template. The temperature must actually be sufficient to synthesize an extension product of each primer which is complementary to each nucleic acid template, but must not be so high as to denature each extension product from its complementary template (i.e., the temperature is generally less than about 80°-90°C).

Depending on the nucleic acid(s) employed, the typical temperature effective for this synthesis reaction generally ranges from about 40° to 80°C, preferably 50°-75°C. The temperature more preferably ranges from about 65°-75°C for Taf DNA polymerase. The period of time required for this synthesis may range from several seconds to 40 minutes or more, depending mainly on the temperature, the length of the nucleic acid, the enzyme, and the complexity of the nucleic acid mixture. The extension time is usually about 30 seconds to three minutes. If the nucleic acid is longer, a longer time period is generally required for complementary strand synthesis. The newly synthesized strand and the complement nucleic acid strand form a double-stranded molecule which is used in the succeeding steps of the amplification process.

In the next step, the strands of the double-stranded molecule are separated by heat denaturation at a temperature and for a time effective to denature the molecule, but not at a temperature and for a period so long that the thermostable enzyme is completely and irreversibly denatured or inactivated. After this denaturation of template, the temperature is decreased to a level which promotes hybridization of the primer to the complementary single-stranded molecule (template) produced from the previous step, as described above.

After this hybridization step, or concurrently with the hybridization step, the temperature is adjusted to a temperature that is effective to promote the activity of the thermostable enzyme to enable synthesis of a primer extension product using as a template both the newly synthesized and the original strands. The temperature again must not be so high as to separate (denature) the extension product from its template, as described above. Hybridization may occur during this step, so that the previous step of cooling after denaturation is not required. In such a case, using simultaneous steps, the preferred temperature range is 50°-70°C.

The heating and cooling steps involved in one cycle of strand separation, hybridization, and extension product synthesis can be repeated as often as needed to produce the desired quantity of the specific nucleic acid sequence. The only limitation is the amount of the primers, thermostable enzyme, and nucleoside triphosphates present. Usually, from 15 to 30 cycles are completed. For diagnostic detection of amplified DNA, the number of cycles will depend on the nature of the sample and the sensitivity of the detection process used after amplification. If the sample is a complex mixture of nucleic acids, more cycles will usually be required to amplify the signal sufficiently for detection. For general amplification and detection, the process is repeated about 15 times. When amplification is used to generate sequences to be detected with labeled sequence-specific probes and when human genomic DNA is the target of amplification, the process is usually repeated 15 to 30 times to amplify the

sequence sufficiently that a clearly detectable signal is produced, i.e., so that background noise does not interfere with detection.

No additional nucleotides, primers, or thermostable enzyme need be added after the initial addition, provided that no key reagent has been exhausted and that the enzyme has not become denatured or irreversibly inactivated, in which case additional polymerase or other reagent would have to be added for the reaction to continue. After the appropriate number of cycles has been completed to produce the desired amount of the specific nucleic acid sequence, the reaction may be halted in the usual manner, e.g., by inactivating the enzyme by adding EDTA, phenol, SDS, or CHCl_3 or by separating the components of the reaction.

The amplification process may be conducted continuously. In one embodiment of an automated process, the reaction mixture may be temperature cycled such that the temperature is programmed to be controlled at a certain level for a certain time. One such instrument for this purpose is the automated machine for handling the amplification reaction developed and marketed by Perkin-Elmer Cetus Instruments. Detailed instructions for carrying out PCR with the instrument are available upon purchase of the instrument.

Taf DNA polymerase is very useful in the diverse processes in which amplification of a nucleic acid sequence by the polymerase chain reaction is useful. The amplification method may be utilized to clone a particular nucleic acid sequence for insertion into a suitable expression vector, as described in United States Patent No. 4,800,159. The vector may be used to transform an appropriate host organism to produce the gene product of the sequence by standard methods of recombinant DNA technology. Such cloning may involve direct ligation into a vector using blunt-end ligation, or use of restriction enzymes to cleave at sites contained within the primers or amplified target sequences. Other processes suitable for Taf polymerase include those described in United States Patent Nos. 4,683,194; 4,683,195; and 4,683,202 and European Patent Publication Nos. 229,701; 237,362; and 258,017; these patents and publications are incorporated herein by reference. In addition, the present enzyme is useful in asymmetric PCR (see Gyllenstein and Erlich, 1988, Proc. Natl. Acad. Sci. USA 85:7652-7656, incorporated herein by reference); inverse PCR (Ochman et al., 1988, Genetics 120:621, incorporated herein by reference); and for DNA sequencing (see Innis et al., 1988, Proc. Natl. Acad. Sci. USA 85:9436-9440, and McConlogue et al., 1988, Nuc. Acids Res. 16(20):9869). Taf polymerase is also believed to have reverse transcriptase activity, (see PCT publication WO 91/09944, which is incorporated herein by reference), and 5'→3' exonuclease activity (also known as structure dependent single strand endonuclease (SDSSE) activity).

The reverse transcriptase activity of the Taf DNA polymerase permits this enzyme to be used in methods for transcribing and amplifying RNA. The improvement of such methods resides in the use of a single enzyme, whereas previous methods have required more than one enzyme.

- 5 The improved methods comprise the steps of: (a) combining an RNA template with a suitable primer under conditions whereby the primer will anneal to the corresponding RNA template; and (b) reverse transcribing the RNA template by incubating the annealed primer-RNA template mixture with Taf DNA polymerase under conditions sufficient for the DNA polymerase to catalyze the polymerization of
- 10 deoxyribonucleotide triphosphates to form a DNA sequence complementary to the sequence of the RNA template.

In another aspect of the above method, the primer which anneals to the RNA template may also be suitable for use in a PCR amplification. In PCR, a second primer which is complementary to the reverse transcribed cDNA strand provides a site for

15 initiation of synthesis of an extension product. As already discussed above, the Taf DNA polymerase is able to catalyze this extension reaction on the cDNA template.

In the amplification of an RNA molecule by Taf DNA polymerase, the first extension reaction is reverse transcription, and a DNA strand is produced as an RNA/cDNA hybrid molecule. The second extension reaction, using the DNA strand as

20 a template, produces a double-stranded DNA molecule. Thus, synthesis of a complementary DNA strand from an RNA template with Taf DNA polymerase provides the starting material for amplification by PCR.

When Taf DNA polymerase is used for reverse transcription from an RNA template, buffers which contain Mn^{2+} may provide improved stimulation of Taf reverse transcriptase activity compared to Mg^{2+} - containing reverse transcription buffers.

25 Consequently, increased cDNA yields may also result from these methods.

As stated above, the product of RNA reverse transcription by Taf DNA polymerase is an RNA/cDNA hybrid molecule. The RNA can be removed or separated from the cDNA by heat denaturation or any number of other known methods including

30 alkali, heat or enzyme treatment. The remaining cDNA strand then serves as a template for polymerization of a complementary strand, thereby providing a means for obtaining a double-stranded cDNA molecule suitable for amplification or other manipulation. The second strand synthesis requires a sequence specific primer and Taf DNA polymerase.

Following the synthesis of the second cDNA strand, the resultant double-

35 stranded cDNA molecule can serve a number of purposes including DNA sequencing, amplification by PCR or detection of a specific nucleic acid sequence. Specific primers useful for amplification of a segment of the cDNA can be added subsequent to the

reverse transcription. Also, it may be desirable to use a first set of primers to synthesize a specific cDNA molecule and a second nested set of primers to amplify a desired cDNA segment. All of these reactions are catalyzed by Taf DNA polymerase.

5 Taf DNA polymerase may also be used to simplify and improve methods for detection of RNA target molecules in a sample. In these methods, Taf DNA polymerase catalyzes: (a) reverse transcription; (b) second strand cDNA synthesis; and, if desired (c) amplification by PCR. The use of Taf DNA polymerase in the described methods eliminates the previous requirement of two sets of incubation conditions which were necessary due to the use of different enzymes for each step.

10 The use of Taf DNA polymerase provides RNA reverse transcription and amplification of the resulting complementary DNA with enhanced specificity and with fewer steps than previous RNA cloning and diagnostic methods. These methods are adaptable for use in laboratory or clinical analysis, and kits for making such analysis simple to perform are an important aspect of the present invention.

15 The RNA which is reverse transcribed and amplified in the above methods can be derived from a number of sources. The RNA template may be contained within a nucleic acid preparation from an organism such as a viral or bacterial nucleic acid preparation. The preparation may contain cell debris and other components, purified total RNA or purified mRNA. The RNA template may also be a population of

20 heterogeneous RNA molecules in a sample. Furthermore, the target RNA may be contained in a biological sample, and the sample may be a heterogeneous sample in which RNA is but a small portion thereof. Examples of such biological samples include blood samples and biopsied tissue samples.

25 Although the primers used in the reverse transcription step of the above methods are generally completely complementary to the RNA template, they need not be. As in PCR, not every nucleotide of the primer must be complementary to the template for reverse transcription to occur. For example, a non-complementary nucleotide sequence may be present at the 5' end of the primer with the remainder of the primer sequence being complementary to the RNA. Alternatively, non-complementary

30 bases can be interspersed into the primer, provided that the primer sequence has sufficient complementarity with the RNA template for hybridization to occur and allow synthesis of a complementary DNA strand.

35 The structure dependent single stranded endonuclease (SDSSE) activity of Taf DNA polymerase I may limit the amount of product produced by PCR, thus creating a plateau phenomenon in the normally exponential accumulation of product. The SDSSE activity may also limit the size of the PCR product produced and the ability to generate PCR product from GC-rich target template. However, SDSSE activity can also be

helpful; see PCT Publication No. _____, based on PCT Application No. 91/05591, filed August 6, 1991, and incorporated herein by reference. SDSSE activity relates to the hydrolysis of phosphodiester bonds. SDSSE activity generally excises 5' terminal regions of double-stranded DNA, thereby releasing 5'-mono- and oligonucleotides.

- 5 The preferred substrate for the SDSSE activity is displaced single-stranded DNA, with hydrolysis of the phosphodiester bond which occurs between the displaced single-stranded DNA and the double-stranded DNA. The cleavage site is a phosphodiester bond in the double-stranded region.

- 10 Site-directed mutagenesis or deletion mutagenesis may be utilized to eliminate the SDSSE activity of a polymerase having such activity. For example, a site-directed mutation of G to A in the second position of the codon for Gly at residue 46 in the Taq DNA polymerase coding sequence has been found to result in an approximately >1,000-fold reduction of SDSSE activity in the protein encoded by the sequence with no apparent change in polymerase activity, processivity or extension rate. This site-
- 15 directed mutation of the Taq DNA polymerase nucleotide sequence results in an amino acid change of Gly (46) to Asp. Glycine 46 is conserved in Thermosipho africanus DNA polymerase, but is present at codon 37, and the same Gly to Asp mutation would have a similar effect on Taf SDSSE activity.

- 20 Gly 46 is found in a conserved AVYGF sequence domain in Taq DNA polymerase; the sequence AVYGL contains the Gly (37) of Taf DNA polymerase. Changing the glycine to aspartic acid within this conserved sequence domain will reduce or eliminate the SDSSE activity. In addition, a deletion of all amino terminal amino acids up to and including the glycine in the AVYGF/L domain will also reduce or eliminate the SDSSE activity of any thermostable DNA polymerase having this
- 25 sequence domain, including the DNA polymerase of Taf.

- One property found in the Taf DNA polymerase, but lacking in native Taq DNA polymerase and native Tth DNA polymerase, is 3'→5' exonuclease activity. This 3'→5' exonuclease activity is generally considered desirable in certain applications, because misincorporated or unmatched bases of the synthesized nucleic acid sequence
- 30 are eliminated by this activity. Therefore, the fidelity of PCR utilizing a polymerase with 3'→5' exonuclease activity (e.g. Taf DNA polymerase) may be increased. The 3'→5' exonuclease activity found in Taf DNA polymerase also decreases the probability of the formation of primer/dimer complexes in PCR. The 3'→5' exonuclease activity in effect prevents any extra dNTPs from attaching to the 3' end of
- 35 the primer in a non-template dependent fashion by removing any nucleotide that is attached in a non-template dependent fashion. The 3'→5' exonuclease activity can eliminate single-stranded DNAs, such as primers or single-stranded template. In

essence, every 3'-nucleotide of a single-stranded primer or template is treated by the enzyme as unmatched and is therefore degraded. To avoid primer degradation in PCR, one can add phosphorothioate to the 3' ends of the primers. Phosphorothioate modified nucleotides are more resistant to removal by 3'→5' exonucleases.

5 "Domain shuffling" or construction of "thermostable chimeric DNA polymerases" may be used to provide thermostable DNA polymerases containing novel properties. For example, substitution of the Taf DNA polymerase coding sequence comprising the 3'→5' exonuclease domain for the Thermus aquaticus DNA polymerase I codons 289-422 would yield a novel thermostable DNA polymerase containing the 5'→3' exonuclease domain of Taq DNA polymerase (1-289), the 3'→5' exonuclease domain of Taf DNA polymerase, and the DNA polymerase domain of Taq DNA polymerase (423-832). Alternatively, the 5'→3' exonuclease domain and the 3'→5' exonuclease domain of Taf DNA polymerase may be fused to the DNA polymerase (dNTP binding and primer/template binding domains) portions of Taq DNA polymerase (ca. codons 423-832). The donors and recipients need not be limited to Taq and Taf DNA polymerases. Tth DNA polymerase provides analogous domains as Taq DNA polymerase. In addition, the enhanced/preferred reverse transcriptase properties of Tth DNA polymerase can be further enhanced by the addition of a 3'→5' exonuclease domain as illustrated above.

20 While any of a variety of means may be used to generate chimeric DNA polymerase coding sequences (possessing novel properties), a preferred method employs "overlap" PCR. In this method, the intended junction sequence is designed into the PCR primers (at their 5'-ends). Following the initial amplification of the individual domains, the various products are diluted (ca. 100 to 1000-fold) and combined, denatured, annealed, extended, and then the final forward and reverse primers are added for an otherwise standard PCR.

25 Thus, the sequence that codes for the 3'→5' exonuclease activity of Taf DNA polymerase can be removed from Taf DNA polymerase or added to other polymerases which lack this activity by recombinant DNA methodology. One can even replace, in a non-thermostable DNA polymerase, the 3'→5' exonuclease activity domain with the thermostable 3'→5' exonuclease domain of Taf polymerase. Likewise, the 3'→5' exonuclease activity domain of a non-thermostable DNA polymerase can be used to replace the 3'→5' exonuclease domain of Taf polymerase (or any other thermostable polymerase) to create a useful polymerase of the invention. Those of skill in the art recognize that the above chimeric polymerases are most easily constructed by recombinant DNA techniques. Similar chimeric polymerases can be constructed by

deleting or by moving the 5'→3' exonuclease domain of one DNA polymerase to another.

The following examples are offered by way of illustration only and are by no means intended to limit the scope of the claimed invention. In these examples, all percentages are by weight if for solids and by volume if for liquids, unless otherwise noted, and all temperatures are given in degrees Celsius.

Example 1

Purification of *Thermosipho africanus* (Taf) DNA Polymerase I

This example describes the isolation of Taf DNA polymerase I from Taf.

10 Taf cells are grown by the method of Huber *et al.*, *supra*. The culture of the Taf cells is harvested by centrifugation after cultivation, in late log phase, at a cell density of 0.2 g to .3 g wet weight/1. Twenty grams of cells are resuspended in 80 ml of a buffer consisting of 50 mM Tris HCl pH 7.5, 0.1 mM EDTA. The cells are lysed and the lysate is centrifuged for two hours at 35,000 rpm in a Beckman TI 45 rotor at 4°C. The
15 supernatant is collected (fraction A) and the protein fraction precipitating between 45 and 75% saturation of ammonium sulfate is collected, dissolved in a buffer consisting of 0.2 M potassium phosphate buffer, pH 6.5, 10 mM 2-mercaptoethanol, and 5% glycerol, and finally dialyzed against the same buffer to yield fraction B.

20 Fraction B is applied to a 2.2 x 30 cm column of DEAE-cellulose, equilibrated with the above described buffer. The column is then washed with the same buffer and the fractions containing protein (determined by absorbance at 280 nM) are collected. The combined protein fraction is dialyzed against a second buffer, containing 0.01 M potassium phosphate buffer, pH 7.5, 10 mM 2-mercaptoethanol, and 5% glycerol, to yield fraction C.

25 Fraction C is applied to a 2.6 x 21 cm column of hydroxyapatite, equilibrated with the second buffer. The column is then washed and the enzyme is eluted with a linear gradient of 0.01-0.5 M potassium phosphate buffer, pH 7.5, containing 10 mM 2-mercaptoethanol and 5% glycerol. Fractions containing DNA polymerase activity are combined, concentrated four-fold using an Amicon stirred cell and YM10 membrane,
30 and dialyzed against the second buffer to yield fraction D.

35 Fraction D is applied to a 1.6 x 28 cm column of DEAE-cellulose, equilibrated with the second buffer. The column is washed and the polymerase is eluted with a linear gradient of 0.01-0.5 M potassium phosphate in the second buffer. The fractions are assayed for contaminating endonuclease(s) and non-specific exonuclease(s) by electrophoretically detecting the change in molecular weight of phage λ DNA or supercoiled plasmid DNA after incubation with an excess of DNA polymerase (for

endonuclease) and after treatment of restriction enzyme cleaved DNA with the DNA polymerase fractions (for exonuclease). Only those DNA polymerase fractions having minimal non-specific nuclease contamination are pooled. To the pool is added autoclaved gelatin in an amount of 250 µg/ml, and dialysis is conducted against the second buffer to yield Fraction E.

Fraction E is applied to a phosphocellulose column and eluted with a 100 ml gradient (0.01-0.8 M KCl gradient in 20 mM potassium phosphate buffer pH 7.5). The fractions are assayed for contaminating endo/exonuclease(s) as described above as well as for polymerase activity (by the method of Kaledin *et al.*) and then pooled. The pooled fractions are dialyzed against the second buffer, and then concentrated by dialysis against 50% glycerol and the second buffer to yield the desired ~100 kilodalton polymerase.

Example 2

Degenerate PCR Priming

Table 1 provides a list of primers used in Examples 2 and 3 along with the sequence identification number for each.

Throughout the examples, A is Adenine; C is Cytidine; G is Guanidine; T is Thymidine; Y is C+T (pYrimidine); S is G + C (Strong interaction; three hydrogen bonds); W is A + T (Weak interaction; two hydrogen bonds); N is A + C + G + T (aNy); and R is G + A (puRine).

Table 1Primer Sequences

	DG144	SEQ ID NO: 3	5'-CGGAATTCNNGGYARRTTATC
	DG145	SEQ ID NO: 4	5'-CGGAATTCNNGGYARRTTGTC
5	DG146	SEQ ID NO: 5	5'-CGGAATTCNNGGRAGRTTATC
	DG147	SEQ ID NO: 6	5'-CGGAATTCNNGGRAGRTTGTC
	DG148	SEQ ID NO: 7	5'-CGGAATTCGCNGTYTTYTCWCC
	DG149	SEQ ID NO: 8	5'-CGGAATTCGCNGTYTTYTCSCC
	DG152	SEQ ID NO: 9	5'-CGAGATCTGARGCNGAYGATGT
10	DG153	SEQ ID NO: 10	5'-CGAGATCTGARGCNGAYGACGT
	DG154	SEQ ID NO: 11	5'-CGAGATCTACNGCNACWGG
	DG155	SEQ ID NO: 12	5'-CGAGATCTACNGCNACSGG
	DG156	SEQ ID NO: 13	5'-CGAGATCTCARAAYATHCCWGT
	DG157	SEQ ID NO: 14	5'-CGAGATCTCARAAYATHCCSGT
15	DG160	SEQ ID NO: 15	5'-CGGAATTCRTCRTGWACCTG
	DG161	SEQ ID NO: 16	5'-CGGAATTCRTCRTGWACTTG
	DG162	SEQ ID NO: 17	5'-CGGAATTCRTCRTGSACCTG
	DG163	SEQ ID NO: 18	5'-CGGAATTCRTCRTGSACTTG
	DG164	SEQ ID NO: 19	5'-CGAGATCTGGNTAYGTWGAAAC
20	DG165	SEQ ID NO: 20	5'-CGAGATCTGGNTAYGTWGAGAC
	DG166	SEQ ID NO: 21	5'-CGAGATCTGGNTAYGTSGAAAC
	DG167	SEQ ID NO: 22	5'-CGAGATCTGGNTAYGTSGAGAC
	DG168	SEQ ID NO: 23	5'-CGGAATTCGTYTCNACRTAWCC
	DG169	SEQ ID NO: 24	5'-CGGAATTCGTYTCNACRTASCC
25	DG173	SEQ ID NO: 25	5'-CGGAATTCATYCKYTCSGC
	DG174	SEQ ID NO: 26	5'-CGGAATTCATRCGYTCSGC
	DG175	SEQ ID NO: 27	5'-CGGAATTCATYCKYTCWGC
	DG176	SEQ ID NO: 28	5'-CGGAATTCATRCGYTCWGC
	DG181	SEQ ID NO: 29	5'-CGGAATTCNGCNGCNGTSCCYTG
30	DG182	SEQ ID NO: 30	5'-CGGAATTCNGCNGCNGTWCCYTG
	DG126	SEQ ID NO: 60	5'-CGGAATTCGCCACATWGGYTC
	DG127	SEQ ID NO: 61	5'-CGGAATTCGCCACATSGGYTC
	DG128	SEQ ID NO: 62	5'-CGAGATCTGGNGAYGAYCCWATG
	DG129	SEQ ID NO: 63	5'-CGAGATCTGGNGAYGAYCCSATG
35	DG130	SEQ ID NO: 64	5'-CGGAATTCATNGGRTCRTCWCC
	DG131	SEQ ID NO: 65	5'-CGGAATTCATNGGRTCRTCSCC
	DG137	SEQ ID NO: 66	5'-CGAGATCTGARGGSGARGA

Table 1 - ContinuedPrimer Sequences

	DG140	SEQ ID NO: 67	5'-CGAGATCTGCNCAYATGGAAGC
	DG141	SEQ ID NO: 68	5'-CGAGATCTGCNCAYATGGAGGC
5	DG150	SEQ ID NO: 69	5'-CGAGATCTGTNTTYGAYGCWAA
	DG151	SEQ ID NO: 70	5'-CGAGATCTGTNTTYGAYGCSAA
	DG158	SEQ ID NO: 71	5'-CGGAATTCACNGGDATRTTTTG
	DG159	SEQ ID NO: 72	5'-CGGAATTCACNGGDATRTTCTG
	DG183	SEQ ID NO: 73	5'-CAATTCCTAATTGCAAATTCGAAATTGACT-
10			GGCGCGCGGCCCGGGCGGCCCC
	MK131	SEQ ID NO: 74	5'-CCCGGATCAGGTTCTCGTC
	MK143	SEQ ID NO: 75	5'-CCGCTGTCCTGGCCACATG

A. Protein Sequence Homology

15 To underscore the power of the degenerate PCR priming method of the invention, information regarding the amino acid and DNA sequence homology between the thermostable DNA polymerases is provided below. Similarity and identity are determined using University of Wisconsin sequence analysis programs (Devereux et al., 1984, Nuc. Acids Res. 12(2):387-395).

Amino Acid Homology

20		<u>Taq</u>		<u>E.Coli</u>	
		<u>Similarity</u>	<u>Identity</u>	<u>Similarity</u>	<u>Identity</u>
	<u>Taq</u>	100	100	60.8	41
	<u>E. coli</u>	60.8	41	100	100
	<u>sps17</u>	91.4	84.1	62.5	41.9
25	<u>ZO5</u>	93.5	86.7	59.6	40.4
	<u>Taf</u>	62.3	41.5	62.3	41.5

DNA Sequence Identity

30	<u>Taq</u>
	<u>sps17</u> 83
	<u>ZO5</u> 85
	<u>Taf</u> 44.6

B. Calculation of T_m

T_m is defined as the temperature at which half of the template is dissociated from the primer. The equation used for the calculation of T_m is derived from the thermodynamic equation:

$$-RT\ln(k_d) = H^\circ - T\Delta S^\circ$$

where R is a constant, T is the temperature (in ° kelvin), k_d is the dissociation constant, H° and S° are the thermodynamic values taken from Breslauer *et al.*, 1986, Proc. Natl. Acad. Sci. USA 83:3746-3748. Rearranging the equation:

$$T = H^\circ / (\Delta S^\circ - 2.3R\log_{10}(K_d)).$$

In the presence of primer excess, the T_m is defined as:

$$T_m = H^\circ / (S^\circ - 2.3R\log_{10}[P]),$$

where $[P]$ is the concentration of primer.

The values of H° and S° taken from Breslauer *et al.* define the T_m in the presence of 1 M NaCl. To correct for the conditions of the PCR buffer (50 mM salt) the following correction is made (taken from Dove *et al.*, J.M.B. 5:359 (1966):

$$T_m(\mu_2) - T_m(\mu_1) = 18.51 \log_{10}(\mu_2/\mu_1),$$

where μ_1 and μ_2 are the ionic strengths of the buffer as defined by equation:

$$\mu = 1/2 \sum (mZ^2).$$

With the equations above, one can calculate the T_m for the primer pools used in the degenerate priming with respect to either Taq or Taf DNA polymerase I gene sequences. The T_m for various pools are shown below; "all" refers to the total primer pool at a concentration of 250 nM, whereas "exact" takes into account the exact concentration of the most completely complementary primer in the pool. The concentration of the most complementary primer is the total concentration divided by the degeneracy of the pool. Lower case letters indicate a base pair mismatch relative to the Taq sequence. The primers were designed to be complementary to the underlined regions; 5' sequences incorporate restriction sites to facilitate cloning of the amplified fragment.

Forward

30	TAQ	CGGGCTACGAGGCGGACGACGT
	DG152	CGaGaTctGARGCNGAyGAtGT
	DG153	CGaGaTctGARGCNGAyGACGT
	CONSENSUS	CGaGaTctGARGCNGAyGAvGT
	TAF	AAGGCTTTGAAGCTGATGACAT

Calculated Tm

	<u>All</u>	<u>Exact</u>
<u>Taq</u>	73°C	65°C
<u>Taf</u>	56°C	47°C

5 REVERSE

TAQ	CTTGACCCCGGGAAGGTTGTC
DG144	CggaAttCCNGGyARRTTaTC
DG145	CggaAttCCNGGyARRTTGTC
DG146	CggaAttCCNGGrAGRTTaTC
10 DG147	CggaAttCCNGGrAGRTTGTC
CONS	CggaAttCCNGGnARRTTTrTC
TAF	TTTAACTCCTGGGATATTATC

Calculated Tm

	<u>All</u>	<u>Exact</u>
15 <u>Taq</u>	68°C	57°C
<u>Taf</u>	53°C	42°C

FORWARD

	TAQ	<u>GGAGGCGGGGTACGTGGAGAC</u>
	DG164	cGAGatctGGNTAyGTwGAaAC
	DG165	cGAGatctGGNTAyGTwGAGAC
5	DG166	cGAGatctGGNTAyGTSGAaAC
	DG167	cGAGatctGGNTAyGTSGAGAC
	CONSENSUS	cGAGatctGGNTAyGTNGARAC
	TAF	<u>GGAAAAAAGGTTATGTTACAAC</u>

Calculated Tm

10		<u>All</u>	<u>Exact</u>
	<u>Taq</u>	62°C	52°C
	<u>Taf</u>	47°C	38°C

REVERSE

	TAQ	<u>ACCAGCTCGTCGTGGACCTG</u>
15	DG160	cggAatTCRTCRTGwACCTG
	DG161	cggAatTCRTCRTGwActTG
	DG162	cggAatTCRTCRTGSACCTG
	DG163	cggAatTCRTCRTGSActTG
	CONSENSUS	cggAatTCRTCRTGNACYTG
20	TAF	<u>ACTAACTCGTCATGAACCTG</u>

Calculated Tm

	<u>All</u>	<u>Exact</u>
<u>Taq</u>	71°C	62°C
<u>Taf</u>	62°C	53°C

25 FORWARD

	TAQ	<u>AGACGGCCACGGCCACGGG</u>
	DG154	cGAgatCtACNGCNACwGG
	DG155	cGAgatCtACNGCNACSGG
	CONSENSUS	cGAgatCtACNGCNACNGG
30	TAF	<u>AAACAGGAACCTTCTACTGG</u>

	<u>Calculated T_m</u>	
	<u>All</u>	<u>Exact</u>
<u>Taq</u>	62°C	52°C
<u>Taf</u>	40°C	29°C

5 REVERSE

	TAQ	ATGAGGTCGGCGGCGGTGCCCTG
	DG181	cgGAatTCNGCNGCNGTSCCyTG
	DG182	cgGAatTCNGCNGCNGTWCcyTG
	CONSENSUS	cgGAatTCNGCNGCNGTNCCyTG
10	TAF	ATTATATCAGCTGCTGTTCCTTG

	<u>Calculated T_m</u>	
	<u>All</u>	<u>Exact</u>
<u>Taq</u>	89°C	78°C
<u>Taf</u>	71°C	58°C

15 C. General Methodology

Standard 2- and 3-temperature profiles were used for screening degenerate primers on TZ05 and Tsps17 (see U.S. Patent application Nos. 590,213, filed September 28, 1990, and 590,466, filed September 28, 1990, both incorporated herein by reference). However, it was noted early in the work with Taf that the standard

20 profiles were inadequate. Figure 1 shows a variety of temperature profiles. Figure 2 shows the effect of temperature profile on the amplification of a purified DNA fragment. Amplification of Taf chromosomal DNA with the degenerate primer pools DG154-DG155 and DG160-DG164 generated the pattern shown in lane 4 (Figure 2). The high molecular weight band is the desired fragment (later confirmed by cloning and

25 DNA sequence analysis). The lower molecular weight bands and the general ethidium bromide staining background represent nonspecific amplification which potentially might mask specific amplification products as well as interfere significantly with cloning of the desired band.

The desired band was purified from an agarose gel and reamplified using

30 temperature profiles 2-5 (Figure 1 and lanes 5-8 of Figure 2). Standard 2-temperature profiles (lanes 5 and 6) were inadequate in generating amplification of the purified band. It appeared that amplification of the small amount of contaminating lower molecular weight bands predominated. In contrast, temperature profile 5 (Figure 3), in which the standard plateau at the lower temperature was replaced by a 5 minute ramp

extending between the lower temperature and 75°C, produced the desired band as the predominant product.

Complex temperature profiles were applied to the screening of degenerate primer pools with the Taf chromosomal DNA as shown in Figure 1. Generally, 5 series of amplifications were performed with many primer pairs. For profiles 1 and 2, an initial 5 cycles of amplification were performed in which a low temperature point was programmed (40°C and 45°C, respectively) followed by 25 cycles in which the low temperature was programmed at 50°C. In profile 3, 30 cycles were performed with the low temperature programmed at 50°C. Profiles 4, 5 and 6 increased the low temperature point by 5°C each and increased the cycle number by 5 or 10 cycles. Measurement of in-tube-temperature showed that the temperature in the tube reached 1 to 2°C above the low temperature setting.

D. Results

Amplification products were obtained from PCR amplification of Taf DNA using the primers listed below. Each amplification yielded products of a molecular weight equal to or greater than that obtained from amplification of Taq DNA using the same degenerate primers. Mismatches between the Taf sequence and the degenerate primers are shown counting from the 3' end of the primer.

DG152-DG153 with DG144-DG147
 -2 (DG152-DG153) and -7 (DG144-DG147)
 DG152-DG153 with DG148-DG149
 -2 (DG152-DG153) and -4 (DG148-DG149)
 DG154-DG155 with DG160-DG163
 -8 (DG154-DG155)
 DG154-DG155 with DG173-DG176
 -8 (DG154-DG155) and -2,-12 (DG173-DG176)
 DG154-DG155 with DG181-DG182
 -8 (DG154-DG155)
 DG156-DG157 with DG168-DG169
 -1,-2,-8 (DG156-DG157)
 DG164-DG167 with DG160-DG163
 -4,-5 (DG164-DG167)

Magnesium concentration is known to affect amplification efficiency. The optimum magnesium concentration depended on both the template and the primer sets used. With DG144-DG147 and DG152-DG153 the optimum magnesium concentration was 3 mM with Taf chromosomal DNA. With the set DG154-DG155 and DG160-

DG163 with Taf DNA, the optimum was 2 mM. For the final buffer, 2 mM was standardly used.

Example 3

Isolation of DNA Fragments Encoding *Thermosiphon africanus* DNA Polymerase I

5 This example presents a degenerate primer method used to isolate DNA fragments that encode Taf DNA polymerase I. In this method, various sets of forward and reverse primers were used in the polymerase chain reaction. These primers were designed to various conserved motifs comprising the 5'→3' nuclease domain, the template/primer binding domain, the dNTP binding domain, or the single-stranded
10 template DNA binding domain of polymerases of known amino acid sequence (E. coli, T7, and Taq). Primer sequences are provided in the Sequence Listing section; Table 1 provides the identification number for each primer.

 Pairs of degenerate primers were screened using the sets of six profiles with the modified 5-minute ramp profiles as described in example 2. The amount of magnesium
15 in the amplification was found to effect the amount of PCR product amplified. The magnesium optimum depended both on the primer pairs chosen as well as the template. For screening of the degenerate primer pools on Taf chromosomal DNA, an average magnesium concentration (2 mM) was chosen.

 The PCR conditions thus consisted of 10 mM Tris, pH 8.3, 50 mM KCl, 2 mM
20 MgCl₂, 200 μM each dNTP, 10 ng chromosomal DNA (at 4.7×10^6 base pairs per genome, or 5.2×10^{-15} g/genome, was equivalent to 3.2×10^{-14} M genome), 500 nM each oligo primer set, and 2.5-5 units Taq polymerase. A total of 16 pairs of primer pools were used, concentrating on sets to amplify the 5' and 3' end of the coding sequence of the polymerase I gene. Of the 16 sets screened, 7 sets (DG152-DG153
25 with DG144-DG147, DG152-DG153 with DG148-DG149, DG154-DG155 with DG173-DG176, DG154-DG155 with DG181-DG182, DG154-DG155 with DG160-DG163, DG156-DG157 with DG168-DG169, DG164-DG167 with DG160-DG163) produced discrete bands of a molecular weight equal or greater to that of the Taq product.

30 Four of the PCR products were selected and cloned (DG152-DG153 with DG148-DG149, DG154-DG155 with DG181-DG182, DG154-DG155 with DG160-DG163, DG164-DG167 with DG160-DG163). For cloning, the amount of the desired product was enriched. The PCR reaction products were extracted with chloroform to remove the oil, extracted with phenol/chloroform to remove the Taq polymerase, ether
35 extracted to remove residual phenol, and concentrated and desalted over a Biogel P-4 spin column (marketed by Bethesda Research Laboratories). The preparations were

electrophoresed on a 3% low melting NuSieve™ GTG agarose gel, and the desired band cut out. The DNA fragment was isolated from the agarose by repeated phenol extractions, ether extractions, and desalting over a Biogel P-4 spin column.

5 The product was then reamplified with the same primer sets used in the initial generation using protocol 3 (Figure 3), in which the setting for the initial low-temperature was 50°C. The oil was removed from the reactions by chloroform extraction, the polymerase by phenol extraction, and residual phenol by ether extraction. Following desalting over a biogel P-4 spin column, the preparations were restricted with EcoRI and BglII according to the manufacturer's specifications. These
10 sites were included in the incorporated primer sequences to allow for subsequent cloning, as shown in Table 2. The restriction enzymes were removed by phenol extraction, the samples concentrated and electrophoresed on a 3% low melting NuSieve™ GTG agarose gel. The target band was isolated as described above.

Vector pBSM13+HindIII::BglII was prepared by restricting plasmid with BglII
15 and EcoRI and dephosphorylating with bacterial alkaline phosphatase. Protein was removed by extraction with phenol/chloroform, and the preparation desalted over a Biogel P-4 spin column. Vector pBSM13+ (purchased from Stratagene) was used to make vector pBSM13+HindIII::BglII by digesting vector pBSM13+ with restriction enzyme HindIII, blunting the ends of the digested vector by Klenow treatment, ligating
20 BglII linkers (5'CAGATCTG), transforming host cells, and selecting transformants which contained a plasmid identical to pBSM13+ but for the absence of a HindIII site and the presence of a BglII site.

A sample of the purified fragment and prepared vector were ligated at 10°C for 15 hours, transformed into DG98, and a sample of the trasformed bacteria plated on
25 ampicillin-containing agar plates. Ampicillin-resistant colonies were isolated, and crude plasmid prepared. The correct clones were identified by comparing the size of the insert following restriction of the crude plasmid with EcoRI and BglII with that of the initial PCR product, and comparing the digestion pattern of both the cloned insert with that of the initial PCR product using a variety of restriction endonucleases. Single-
30 stranded DNA was prepared from selected clones and the sequence determined by standard dideoxy sequencing methods. The amino acid sequence deduced from the DNA sequence contained significant homology to known polymerase sequences, suggesting that the PCR products were in fact derived from a Taf polymerase gene.

This strategy resulted in the successful amplification and cloning of various
35 regions of the Taf DNA polymerase gene with the primer pairs shown in Table 2. The primers were designed to be complementary to sequences coding for the amino acid sequences shown; upstream sequences incorporate restriction sites used in the cloning

of the amplified product. In Table 2, the amino acid sequence shown below the DNA sequence for the reverse primer is given in the carboxy to amino direction and encoded by the complement of the sequence. The primers shown in Table 2 are characterized as follows.

5 Synthetic oligodeoxyribonucleotides DG148 and DG149 are two different 32-fold degenerate (each) 22 mer pools designed as "reverse" primers to one of the motifs in the 5' to 3' exonuclease domain (3' most 14 nucleotides) of thermostable DNA polymerases. The primers are designed to complement the (+)-strand DNA sequence that encodes the motif Gly-Glu-Lys-Thr-Ala and which corresponds
10 identically to Taq DNA polymerase amino acids 200 through 204 and to Tth DNA polymerase amino acids 201 through 205. This motif is found in a DNA polymerase gene in all Thermus species. The combined primer pool is 64-fold degenerate and the primers encode an EcoRI recognition sequence at their 5'-ends.

 Synthetic oligodeoxyribonucleotides DG152 and DG153 are two different
15 16-fold degenerate (each) 23 mer pools designed as "forward" primers to one of the motifs in the 5' to 3' exonuclease domain (3' most 14 nucleotides) of thermostable DNA polymerases. This motif is the amino acid sequence Glu-Ala-Asp-Asp-Val and corresponds identically to Taq DNA polymerase amino acids 117 through 121 and to Tth DNA polymerase amino acids 118 through 122. This motif is found in a DNA
20 polymerase gene in all Thermus species. The combined primer pool is 32-fold degenerate and the primers encode a BglII recognition sequence at their 5'-ends.

 Synthetic oligodeoxyribonucleotides DG154 and DG155 are two different 32-fold degenerate (each) 19 mer pools designed as "forward" primers to one of the motifs in the primer:template binding domain (3' most 11 nucleotides) of thermostable
25 DNA polymerases. This motif is the tetrapeptide amino acid sequence Thr-Ala-Thr-Gly and corresponds identically to Taq DNA polymerase amino acids 569 through 572, and to Tth and Thermus species ZO5 DNA polymerase amino acids 571 through 574. This motif is found in a DNA polymerase gene in all Thermus species. The combined primer pool is 64-fold degenerate and the primers encode a BglII recognition sequence
30 at their 5'-ends.

 Synthetic oligodeoxyribonucleotides DG160 through DG163 are four different 8-fold degenerate (each) 20 mer pools designed as "reverse" primers to one of the motifs in the template binding domains (3' most 14 nucleotides) of thermostable DNA polymerases. The primers are designed to complement the (+)-strand DNA sequence
35 that encodes the motif Gln-Val-His-Asp-Glu and which corresponds identically to Taq DNA polymerase amino acids 782 through 786, and to Tth and Thermus species ZO5 DNA polymerase amino acids 784 through 788. This motif is found in a DNA

polymerase gene in all Thermus species. The combined primer pool is 32-fold degenerate and the primers encode an EcoRI recognition sequence at their 5'-ends.

5 Synthetic oligodeoxyribonucleotides DG164 through DG167 are four different 16-fold degenerate (each) 22 mer pools designed as "forward" primers to one of the motifs in the template binding domain (3' most 14 nucleotides) of thermostable DNA polymerases. This motif is the pentapeptide amino acid sequence Gly-Tyr-Val-Glu-Thr and corresponds identically to Taq DNA polymerase amino acids 718 through 722, to Tth and Thermus species ZO5 DNA polymerase amino acids 720 through 724. This motif is found in a DNA polymerase gene in most Thermus species. The combined primer pool is 64-fold degenerate and the primers encode a BglII recognition sequence at their 5'-ends.

15 Synthetic oligodeoxyribonucleotides DG181 and DG182 are two different 256-fold degenerate (each) 23 mer pools designed as "reverse" primers to one of the motifs in the template binding domain (3' most 17 nucleotides) of thermostable DNA polymerases. The primers are designed to complement the (+)-strand DNA sequence that encodes the motif Gln-Gly-Thr-Ala-Ala-Asp and which corresponds identically to Taq DNA polymerase amino acids 754 through 759 and to Tth DNA polymerase amino acids 756 through 761. This motif is found in a DNA polymerase gene in all Thermus species. The combined primer pool is 512-fold degenerate and the primers encode an EcoRI recognition sequence at their 5'-ends.

Table 2
Degenerate Primer Sets That Produced
Correct Regions of Taf Polymerase Gene

<u>Forward Primer</u>	<u>Sequence</u>	<u>Reverse Primer</u>	<u>Sequence</u>
DG152 - DG153	GluAlaAspVal 5'CGAGATCTGARGCNGAYGATGT	DG148 - DG149	5'CGGAATTCGCNGTYYTTCWCC AlaThrLysGluGly
	GluAlaAspVal 5'CGAGATCTGARGCNGAYGACGT		5'CGGAATTCGCNGTYYTTCSCC AlaThrLysGluGly
DG164 - DG167	GlyTyrValGluThr 5'CGAGATCTGGNTAYGTWGAAC	DG160 - DG163	5'CGGAATTCRTCTGTGACCTG GluAspHisValGln
	GlyTyrValGluThr 5'CGAGATCTGGNTAYGTWAGAC		5'CGGAATTCRTCTGTGACTTG GluAspHisValGln
	GlyTyrValGluThr 5'CGAGATCTGGNTAYGTSGAAC		5'CGGAATTCRTCTGTGSACCTG GluAspHisValGln Asp
	GlyTyrValGluThr 5'CGAGATCTGGNTAYGTSGAGAC		5'CGGAATTCRTCTGTGSACTTG GluAspHisValGln Asp

Table 2 - Continued
Degenerate Primer Sets That Produced
Correct Regions of Taf Polymerase Gene

Forward Primer	Sequence	Reverse Primer	Sequence
DG154 - DG155	ThrAlaThrGly 5'CGAGATCTACNGCNACWGG	DG160 - DG163	5'CGGAATTCRTCTGTGACCTG GluAspHisValGln Asp
	ThrAlaThrGly 5'CGAGATCTACNGCNACSGG		5'CGGAATTCRTCTGTGACTTG GluAspHisValGln Asp
			5'CGGAATTCRTCTGTGACCTG GluAspHisValGln Asp
			5'CGGAATTCRTCTGTGACTTG GluAspHisValGln Asp
DG154-DG155	ThrAlaThrGly 5'CGAGATCTACNGCNACWGG	DG181 - DG182	5'CGGAATTCGNCNGCNGTSCCYTG AspAlaAlaThrGlyGln Glu
	ThrAlaThrGly 5'CGAGATCTACNGCNACSGG		5'CGGAATTCGNCNGCNGTWCCYTG AspAlaAlaThrGlyGln Glu

The entire coding sequence for Taf polymerase was then identified. Taf chromosomal DNA was digested with BamHI, BglII, ClaI, EcoRI, HindIII, KpnI, PstI, SacI, and SalI according to the manufacturer's specifications and electrophoresed (with radioactively labeled HindIII-digested lambda DNA as a molecular weight marker) on a 0.7% agarose gel. The gel was acid nicked in 0.25 N HCl (30 minutes), and transferred to HybondN⁺™ nylon membrane (marketed by Amersham) by capillary action in 0.4 N NaOH for 19 hours. The DNA was cross-linked to the membrane by irradiating with 50 mJoules by a Stratalinker™ 1800 (marketed by Stratagene) and treated with prehybridization buffer.

Radioactive probes were generated from the regions encoded between the primer pairs DG160-DG163 and DG164-DG167, and DG144-DG147 to DG152-DG153. Initial PCR product was generated, confirmed by restriction analysis, and purified as described above. Amplification was then repeated using a sample of the purified PCR product as the template, and replacing the dGTP in amplification with 50 μM α-³²P-dGTP. The oil was removed by chloroform extraction, the polymerase by extraction with phenol/chloroform, the sample concentrated, and unincorporated label removed by desalting over a Biogel P4 spin column. The preparation was electrophoresed on a 3% low melting NuSieve™ GTG agarose gel, and the target radioactively labeled band isolated as described above.

The 3' end of the coding sequence for the polymerase gene was identified by hybridizing the chromosomal blots with 3.6 x 10⁶ cpm of probe Taf DG160-DG163 to DG164-DG167 at 50°C for 17 hours. The blots were washed twice with 2 X SSPE, 0.1% SDS at 23°C for 10 to 25 minutes, then 1 X SSPE, 0.1% SDS at 52°C for 20 minutes and autoradiographed. Discrete bands hybridizing to the probe were identified and their molecular weights determined by comparison to the radioactively labeled lambda markers. Thus, the 3' end of gene was located within the following fragments.

	<u>Enzyme</u>	<u>Molecular weight (bp) of fragment containing 3'end</u>
	<u>BamHI</u>	6,000 or 21,000
	<u>BglII</u>	2,330
	<u>ClaI</u>	8,100
5	<u>EcoRI</u>	4,900 or 6,800
	<u>HindIII</u>	5,350, 3,000 or 1,680
	<u>KpnI</u>	19,500
	<u>PstI</u>	1,410 or 18,000
	<u>SacI</u>	>23,000
10	<u>SalI</u>	>23,000

The portion of gene encoding the 5' end of the polymerase sequence was then identified. The 3' probe was removed by boiling the blots in 0.5% SDS, and the membranes hybridized to 3.0×10^6 cpm of Taf probe DG152-DG153 to DG148-DG149 at 66°C for 22 hours. The membranes were washed twice in 2 X SSPE, 0.1 % SDS at 23°C for 10 minutes and 1 X SSPE, 0.1% SDS at 65°C for 30 minutes, and autoradiographed. The following fragments were therefore identified as containing sequences that code for the 5' end of the polymerase gene:

	<u>Enzyme</u>	<u>Molecular weight (bp) of fragment containing 5'end</u>
	<u>BamHI</u>	20,000
20	<u>BglII</u>	2,280
	<u>ClaI</u>	7,500
	<u>EcoRI</u>	6,800
	<u>HindIII</u>	2,350
	<u>KpnI</u>	19,500
25	<u>PstI</u>	16,000
	<u>SacI</u>	21,000
	<u>SalI</u>	>23,000

From the two hybridization patterns, it was determined that the gene contains both BglII and HindIII sites. In addition, a 6,800 bp EcoRI fragment contains sequences coding for both the 3' and 5' ends of the polymerase sequence.

The 6,800 bp EcoRI fragment containing the entire gene was then cloned from the chromosome. Taf chromosomal DNA (20 μ g) was digested with EcoRI according to the manufacturer's specifications. The completion of digestion was confirmed by electrophoresis of a sample on a 0.7% agarose gel, acid nicking, transferring to HybondN⁺™ in 0.4 N NaOH, and probing with radioactively labeled Taf PCR product extending between DG160-DG163 and DG164-DG167. The complete digest was size

fractionated by electroelution on a 0.5% SeaKem™ agarose LE gel in TEA and fractions collected. The fractions containing the target EcoRI fragment were identified by electrophoresis on a 0.7% agarose gel, which was then acid nicked, transferred to HybondN+™ in 0.4 M NaOH, and hybridized to radioactively labeled Taf PCR product
5 extending between DG160-DG163 and DG164-DG167. The fractions containing the 6,800 bp EcoRI fragment were pooled, concentrated, and desalted over a Biogel P4 spin column.

Three vectors were prepared by digesting pBR322, pUC13, and pBSM13+HindIII::BglII with EcoRI, dephosphorylating with bacterial alkaline
10 phosphatase, extracting with phenol/chloroform and then ether, and desalting over a biogel P-4 spin column. The size fractionated material containing the 6,800 bp-EcoRI fragment was ligated into the vectors, transformed into DG98, and the transformation mixture plated onto ampicillin-containing agar plates.

Following growth at 37°C for 16 hours, the colonies were lifted onto
15 nitrocellulose filters, lysed with triton lytic buffer, the DNA denatured using 0.5 M NaOH, 1 M NaCl, neutralized with 0.5 M Tris, pH 8.0, 1.0 M NaCl, rinsed with 0.3 M NaCl, 10 mM Tris, pH 7.6, 1 mM EDTA, pH 8.0, and baked at 80°C for 3 hours. The filters were incubated with prehybridization buffer at 65°C for 1 hour and hybridized with 4.4 x 10⁵ CPM of radioactively labeled Taf PCR product extending
20 between DG160-DG163 and DG164-DG167 for 15 hours at 50°C. The filters were washed in 5 X SSC, 0.1 % SDS at 23°C for 16 minutes, 2 X SSC, 0.1% SDS at 23°C for 30 minutes, and autoradiographed.

Probe positive colonies were inoculated into broth containing ampicillin and methicillin and grown at 37°C. The correct clones were identified by isolating plasmid
25 DNA followed by restriction enzyme analysis. Clones containing a 6.8 kb insert were identified by restriction with EcoRI. The correct clones were further identified by restriction analysis with HindIII, HindIII and EcoRI or BglII, because it was determined in the chromosomal mapping that the polymerase gene contained both HindIII and BglII sites.

30 For further confirmation, the restriction digests of the suggested clones were electrophoresed on a 0.7% agarose gel, and the DNA bands transferred to HybondN+™ and probed with radioactively labeled Taf PCR product extending between DG160-DG163 and DG164-DG167, and subsequently with radioactively labeled Taf PCR product extending between DG144-DG147 and DG152-DG153 as previously
35 described. Several clones were confirmed as correct (52-1, 52-2, 52-3, 52-6, 52-7, and 52-9).

To facilitate sequencing and subsequent manipulation of the polymerase gene for the construction of expression vectors, a smaller 3,000 bp EcoRV fragment was subcloned from the larger 6,800 bp EcoRI fragment. Clone 52-1, containing the 6,800 EcoRI fragment was digested with EcoRV, according to the manufacturer's specifications, concentrated, desalted over a biogel P-4 spin column, and electrophoresed on a 1% low melting NuSieve™ GTG agarose gel. The target band was then purified as previously described.

For the vector, pBSM13+HindIII::BglII was restricted with SmaI and dephosphorylated by bacterial alkaline phosphatase. The protein was removed by phenol/chloroform extraction, and the preparation desalted over a Biogel P-4 spin column. A sample of the vector and purified fragment was ligated with T4 DNA ligase and T4 RNA ligase at 23°C for 7 hours, transformed into DG98 and the transformation mixture plated on ampicillin-containing agar plates. Ampicillin-resistant colonies were selected and grown in liquid broth, and crude plasmid preparations isolated.

The size of the insert was determined by restriction with EcoRI and BamHI, which cut the vector on both sides of the SmaI site that contained the insert. The identity of the insert was further confirmed by restriction with BglII, a site previously determined to be within the gene from the mapping of the chromosome (described above), EcoRI with ClaI, and EcoRI with SpeI. Clones were identified which contained the polymerase gene in both orientations. The orientation that placed the coding sequence in position for expression from the lac promoter was designated pBSM:TafEcoRV.

Example 4

Construction of Thermosipho africanus DNA Polymerase I Expression Vectors

The entire Taf DNA polymerase I coding sequence can be isolated from Taf genomic DNA on an approximately 3 kb EcoRV fragment. This EcoRV fragment was isolated and cloned into the Stratagene™ vector pBSM13+, which had first been digested with restriction enzyme SmaI. The resulting vector was designated pBSM:TafEcoRV, and the orientation of the Taf gene EcoRV DNA fragment is such that the lac promoter, ribosome-binding site (RBS), and ATG start codon for the coding sequence of beta-galactosidase from the pBSM13+ vector are positioned for expression of the Taf DNA polymerase I coding sequence. The ATG start codon of the Taf DNA polymerase I coding sequence is about 20 bp from the EcoRV restriction enzyme recognition site, which is, in turn, about 84 bp from the ATG of the beta-galactosidase coding sequence.

Oligonucleotide site-directed mutagenesis was then used to alter the carboxy terminus encoding region of the Taf DNA polymerase I coding sequence in plasmid pBSM:TafEcoRV. Single-stranded plasmid DNA was prepared by infecting a log phase culture of DG98 harboring the plasmid with helper phage R408. Single-stranded

5 DNA was recovered and purified via electroelution. Gapped-duplex DNA was formed between the single-stranded pBSM:TafEcoRV and the large PvuII fragment of vector pBSM13+, and then the gapped duplex was annealed with mutagenic oligomer, either DG233 or DG234. Extension and ligation of the reactions containing mutagenic oligomers annealed to gapped duplex was performed, and the mixtures were

10 transformed into DG101. Transformed colonies on nitrocellulose filters were screened by hybridization with γ -³²P-labeled oligomer DG235. Mini-screen DNA prepared from positive single colonies was analyzed by restriction analysis to confirm the presence of a new BamHI site, loss of a BglII site, and the appropriate PvuII pattern. DNA sequence analysis confirmed the mutagenesis.

15 The sequences of the mutagenic and probe oligomers are shown below.

DG233 SEQ ID NO: 31 5'-GCGAATTCGAGCTCGGTACC-
GGATCCTCATTCCCACTCTTTTCC

DG234 SEQ ID NO: 32 5'-CCTTTACCCCAGGATCCTCAT-
TCCCACTCTTTTCC

20 DG235 SEQ ID NO: 33 5'-GATCCTCATTCCCACTC

Mutagenesis with DG233 changed the TAA stop codon to TGA, created a BamHI restriction site immediately following the new TGA stop codon, and deleted Taf and vector sequences to the KpnI site in the polylinker of the vector, a deletion of 213 bp. One of the correct mutants from the DG233 mutagenesis was designated pTaf01.

25 Mutagenesis with DG234 changed the TAA stop codon to TGA and created a new BamHI site directly downstream of the TGA stop, but deleted no Taf or vector sequences downstream of the BamHI site. One of the correct mutants from the DG234 mutagenesis was designated pBSM:TafRV3' and can be used to construct expression vectors as illustrated with pTaf01, below.

30 Oligonucleotide site-directed mutagenesis was used to alter the 5'-end of the Taf DNA polymerase I gene in pTaf01. Mutagenesis was as described above, using mutagenic oligonucleotide DG248 to insert an NcoI restriction site at the ATG start of the Taf DNA polymerase I coding sequence and to delete vector and Taf sequences to make the lacZ ATG start codon the start codon for the Taf DNA polymerase I coding

35 sequence. Transformed colonies on nitrocellulose filters were screened by hybridization with γ -³²P-labeled oligonucleotide DG237. The sequences of the mutagenic and probe oligomers are shown below.

DG248 SEQ ID NO: 34 5'-CAAATAGAAACATCTTTCCC-
ATGGCTGTTTCTCTGTGTGAAATTG
DG237 SEQ ID NO: 35 5'-GAAACAGCCATGGGAAAG

5 Mini-screen DNA prepared from positive colonies was subjected to restriction analysis to confirm the presence of the new NcoI site and the deletion. DNA sequence analysis was also performed to ensure that the correct sequence was obtained. The correct plasmid was designated pTaf02. IPTG-induced cultures harboring pTaf02 expressed heat-stable polymerase activity at 24 units per mg crude extract protein (where a pBSM13+ control culture was 0.04 units per mg crude extract protein, and the
10 pBSM:TafEcoRV culture was 6.5 units per mg crude extract protein).

The 2.7 kb NcoI-BamHI DNA fragment comprising the Taf DNA polymerase I coding sequence in pTaf02 was cloned into four P_L expression plasmids, pDG182-pDG185, which had been digested with NcoI and BamHI. Plasmids pDG182 and pDG184 are derivatives of pDG160, and pDG183 and pDG185 are derivatives of
15 pDG161. The construction of plasmids pDG160 and pDG161 is described in Example 6 of Serial No. 455,967, filed December 22, 1989, the entire disclosure of which is incorporated herein by reference. The preferred host for such expression vectors is E. coli K12 strain DG116, and culture of the host cells and induction of expression is carried out as described in Example 7 of Serial No. 455,967.

20 To construct expression vectors pDG182-pDG185, plasmids pDG160 and pDG161 were digested with restriction enzymes MroI and KpnI, and the smaller of the resulting two fragments was replaced with a duplex adaptor linker, either FL42/FL43 or FL44/FL45, and the vector recircularized by ligation. The sequence of the duplex adaptor linkers FL42 (SEQ. ID NO: 36); FL43 (SEQ. ID NO: 37); FL44 (SEQ. ID
25 NO: 38); and FL45 (SEQ. ID NO: 39) are shown below.

FL42/FL43

5'-CCGGAAGAAGGAGAAAATACCATGGGCCCCGGTAC-3'

3'-TTCTTCCTCTTTTATGGTACCCGGGC-5'

FL44/FL45

5 5'-CCGGAGGAGAAAATCCATGGGCCCCGGTAC-3'

3'-TCCTCTTTTAGGTACCCGGGC-5'

The following table describes the properties of plasmids pDG182-pDG185.

	Vector	Amp ^R or Tet ^R	RBS	Site at ATG	Oligonucleotide Duplex Cloned into pDG160 or pDG161
10	pDG182	Amp	T7	<u>NcoI</u>	FL42/FL43-pDG160
	pDG184	Amp	N	<u>NcoI</u>	FL44/FL45-pDG160
	pDG183	Tet	T7	<u>NcoI</u>	FL42/FL43-pDG161
	pDG185	Tet	N	<u>NcoI</u>	FL44/FL45-pDG161

In addition to the features tabulated above, the pDG182-pDG185 vectors also contain the δ -toxin positive retroregulator from Bacillus thuringiensis and point mutations in the RNA II gene which render the plasmids temperature sensitive for copy number.

Derivatives of pDG182-pDG185 containing the 2.7 kb NcoI to BamHI fragment are pTaf03 (from pDG182), pTaf04 (from pDG183), pTaf05 (from pDG184), and pTaf06 (from pDG185). These plasmids produce Taf DNA polymerase I activity when expression is induced.

Example 5PCR with Taf DNA Polymerase

About 1.25 units of the Taf DNA polymerase purified in Example 1 is used to amplify sequences from Tth genomic DNA. The reaction volume is 50 μ l, and the reaction mixture contains 50 pmol of primer DG73, 10^5 to 10^6 copies of the Tth genome ($\sim 2 \times 10^5$ copies of genome/ng DNA), 50 pmol of primer DG74, 200 μ M of each dNTP, 2 mM $MgCl_2$, 10 mM Tris-HCl, pH 8.3, 50 mM KCl, and 100 μ g/ml gelatin (optionally, gelatin may be omitted).

The reaction is carried out on a Perkin-Elmer Cetus Instruments DNA Thermal Cycler. Twenty to thirty cycles of 96°C for 15 seconds; 50°C for 30 seconds, and 75°C for 30 seconds are carried out. At 20 cycles, the amplification product (160 bp in size) can be faintly seen on an ethidium bromide stained gel, and at 30 cycles, the product is readily visible (under UV light) on the ethidium bromide stained gel.

The PCR may yield fewer non-specific products if fewer units of Taf DNA polymerase are used (i.e., 0.31 units/50 µl reaction). Furthermore, the addition of a non-ionic detergent, such as laureth-12, to the reaction mixture to a final concentration of 1% can improve the yield of PCR product.

5 Primers DG73 and DG74 are shown below:

DG73 SEQ ID NO: 40 5'-TACGTTCCCGGGCCTTGTAC

DG74 SEQ ID NO: 41 5'-AGGAGGTGATCCAACCGCA

Example 6

Expression of modified Taf polymerase

10 In an effort to increase the expression levels, site specific mutagenesis was performed to (1) remove the predicted hairpin structure from codons 2 to 6 of the coding sequence; and (2) change codons 2, 5, 6, 7, 9, and 11 to codons used more commonly in E. coli than the codons present in the native sequence. Mutagenic primers, FR404 or FR405, each containing a modified sequence were synthesized and
15 phosphorylated. The modified codon 9 and codon 10 form a KpnI site. Single-stranded pTaf02 was prepared by coinfecting a log phase culture of DG101 containing the plasmid with the helper phage R408, commercially available from Stratagene. A "gapped duplex" of single stranded pTaf02 and the large fragment from the PvuII digestion of pBSM13+ was created by mixing the two plasmids, heating to boiling for
20 2 minutes, and cooling to 65°C for 5 minutes. Mutagenic primer FR404 or FR405 was then annealed with the "gapped duplex" by mixing, heating to 80°C for 2 minutes, and then cooling slowly to room temperature. The remaining gaps were filled by extension with Klenow and the fragments ligated with T4 DNA ligase, both reactions taking place in 200 µM of each dNTP and 40 µM ATP in standard salts at 37°C for 30 minutes.

25 The resulting circular fragment was transformed into DG101 host cells by plate transformations on nitrocellulose filters. Duplicate filters were made and the presence of the correct plasmid was detected by probing with a $\gamma^{32}\text{P}$ -phosphorylated probe; FR401 was used to screen for the product of mutagenesis with FR404 and FR399 was used to screen for the product of mutagenesis with FR405. Mini-screen DNA prepared
30 from positive colonies was subjected to restriction analysis to confirm the presence of the NcoI site from pTaf02 and the introduced KpnI site, after which the DNA sequence was confirmed. Two expression vectors were produced by the above protocol; the vector created using FR404 was designated pTaf07 and the vector created using FR405 was designated pTaf08.

35 The oligonucleotide sequences used in this example are listed below.

<u>Oligo</u>	<u>SEQ ID NO:</u>	<u>Sequence</u>
FR399	SEQ ID NO: 42	5'-TAAGATGTTCTTGTTTC
FR401	SEQ ID NO: 43	5'-TAAGATGTTCCCTGTTTC
FR404	SEQ ID NO: 44	5'-ATACTAAACCGGTACCAT-
5		CGAACAGGAACATCTTACCCATGGC
FR405	SEQ ID NO: 45	5'-ATACTAAACCGGTACCA-
		TCGAACAAGAACATCTTACCCATGGC

Example 7

Expression of Truncated Taf Polymerase

10 Mutein forms of the Taf polymerase lacking 5' → 3' exonuclease activity were constructed by introducing deletions in the 5' end of the gene. Both 279 and 417 base pair deletions were created using the following protocol; an expression plasmid was digested with restriction enzymes to excise the desired fragment, the fragment ends were repaired with Klenow and all four dNTP's, to produce blunt ends, and the

15 products were ligated to produce a new circular plasmid with the desired deletion. To express a 93 kilodalton, 5' → 3' exonuclease-deficient form of Taf polymerase, a 279 bp deletion comprising amino acids 2-93 was generated. To express an 88 kilodalton, 5' → 3' exonuclease-deficient form of Taf polymerase, 417 bp deletion comprising amino acids 2-139 was generated.

20 To create a plasmid with codons 2-93 deleted, pTaf03 was digested with NcoI and NdeI and the ends were repaired by Klenow treatment. The digested and repaired plasmid was diluted to 5 µg/ml and ligated under blunt end conditions. The dilute plasmid concentration favors intramolecular ligations. The ligated plasmid was transformed into DG116. Mini-screen DNA preparations were subjected to restriction

25 analysis and correct plasmids were confirmed by DNA sequence analysis. The resulting expression vector created by deleting a segment from pTaf03 was designated pTaf09. A similar vector created from pTaf05 was designated pTaf10.

Expression vectors also were created with codons 2-139 deleted. The same protocol was used with the exception that the initial restriction digestion was performed

30 with NcoI and BglII. The expression vector created from pTaf03 was designated pTaf11 and the expression vector created from pTaf05 was designated pTaf12.

Example 8

Expression Vectors With T7 Promoters

Expression efficiency can be altered by changing the promoter and/or ribosomal binding site (RBS) in an expression vector. The T7 gene10 promoter and RBS were used to control the expression of Taf DNA polymerase in expression vector pTaf13, and the T7 gene10 promoter and the gene N RBS were used to control the expression of Taf DNA polymerase in expression vector pTaf14. The construction of these vectors took advantage of unique restriction sites present in pTaf05: an AflII site upstream of the promoter, an NcoI site downstream of the RBS, and a BspEI site between the promoter and the RBS. The existing promoter was excised from pTaf05 and replaced with a synthetic T7 gene 10 promoter using techniques similar to those described in the previous examples.

The synthetic insert was created from two overlapping synthetic oligonucleotides. To create pTaf13, equal portions of FR414 and FR416 were mixed, heated to boiling, and cooled slowly to room temperature. The hybridized oligonucleotides were extended with Klenow to create a full-length double-stranded insert. The extended fragment was then digested with AflII and NcoI, leaving the appropriate sticky ends. The insert was cloned into plasmid pTaf05 digested with AflII and NcoI. DG116 host cells were transformed with the resulting plasmid and transformants screened for the desired plasmid.

The same procedure was used in the creation of pTaf14, except that FR414 and FR418 were used, and the extended fragment was digested with AflII and BspEI. This DNA fragment was substituted for the P_L promoter in plasmid pTaf05 that had been digested with AflII and BspEI.

Plasmids pTaf13 and pTaf14 are used to transform E. coli host cells that have been modified to contain an inducible T7 RNA polymerase gene. However, because T7 RNA polymerase may not recognize the δ -toxin retroregulator terminator sequence present in the plasmid vector, it may be desirable to clone the T7 gene 10 terminator sequence into pTaf13 or pTaf14.

The T7 gene 10 terminator sequence was first cloned into a small, high copy number E. coli cloning vector, pUC19, available as ATCC 37254 (see Yanisch-Perron, et al., 1985, Gene 33:103-119). Synthetic oligonucleotides, HW73 and HW75, were annealed to provide the T7 gene 10 terminator sequence flanked by HindIII sticky ends. The pUC19 plasmid was digested with HindIII and ligated with the HW73/HW75 duplex. The resulting plasmid, designated pTW66, was transformed into DG101 and screened for orientation by restriction enzyme digestion and DNA sequence analyses.

A second vector was created from pUC19 by inserting the T7 promoter sequence. Synthetic oligonucleotides, HW71 and HW72, were annealed to provide the T7 promoter sequence flanked by BamHI sticky ends. The pUC19 plasmid was digested with BamHI and ligated with the HW71/HW72 duplex. The resulting
5 plasmid, designated pTW64, was transformed into DG101 and screened for orientation by restriction analyses and sequence analysis.

A 95 bp fragment containing the T7 promoter was isolated from pTW64 by digestion with EcoRI and HindIII and separation of the restriction fragments by gel electrophoresis. The pTW66 plasmid was digested with EcoRI and HindIII and ligated
10 with the purified fragment from the digestion of pTW64. The resulting vector, designated pTW67, contains both the T7 promoter sequence and gene 10 terminator sequence.

The T7 gene 10 terminator sequence is excised from the pTW67 vector by digestion with XhoI and SalI. The vector is also cut with PvuII to reduce background.
15 The pTaf13 vector is cut with SalI which cleaves at a unique site just downstream of the existing terminator. Digestions with XhoI and SalI leave the same sticky end for ligation. The fragment containing the T7 gene 10 terminator sequence is ligated with the cleaved pTaf13. The resulting plasmid, designated pTaf16, is transformed into MM294 and screened for orientation.

20 The expression plasmid pTaf16, which contains the T7 gene10 promoter, RBS, and the T7 gene 10 terminator, is transformed into an *E. coli* host cell modified to contain an inducible T7 RNA polymerase gene.

The oligonucleotides used in the construction of these vectors are listed below.

25	FR414	SEQ ID NO: 46	5'-TCAGCTTAAGACTTCGAAATTAATA- CGACTCACTATAGGGAGACCACAA- CGGTTTCCTC
	FR416	SEQ ID NO: 47	5'-TCGACCATGGGTATATCTCCTT- CTTAAAGTTAAACAAAATTATTC- TAGAGGGAAACCGTTG
30	FR418	SEQ ID NO: 48	5'-TCAGTCCGGATAAACAAAA- TTATTTCTAGAGGGAAACCGTTG
	HW71	SEQ ID NO: 49	5'-GATCACTTCGAAATTAA- TACGACTCACTATAGGGAGACCG
35	HW72	SEQ ID NO: 50	5'-GATCCGGTCTCCCTATAGTGAG- TCGTATTAATTTCGAAGT

HW73 SEQ ID NO: 51 5'-AGCTTTAAAGATCTAATAACTA-
GCATAACCCCTTGGGGCCTCTAAA-
CGGGTCTTGAGGGGTTTTTGCTGA-
CTCGAG

5 HW75 SEQ ID NO: 52 5'-AGCTCTCGAGTCAGCAAAAAACCCC-
TCAAGACCCGTTTAGAGGCCCCCAA-
GGGGTTATGCTAGTTATTAGATCTTTAA

Example 9

Translational Coupling

10 To effect the translation of the Taf polymerase gene, translationally coupled derivatives of Taf expression vectors were constructed. An expression vector was constructed with a secondary translation initiation signal and short coding sequence just upstream of the Taf gene coding sequence such that the stop codon for the short coding sequence is coupled, i.e., overlaps, with the ATG start codon for the Taf gene coding sequence. Translation of the short coding sequence brings the ribosome into close

15 proximity with the Taf gene translation initiation site, thereby enhancing translation of the Taf gene.

Translationally coupled Taf expression vectors were constructed with the translation initiation signal and first ten codons of the T7 bacteriophage major capsid protein (gene 10) fused in-frame to the last six codons of the E. coli TrpE gene placed

20 upstream of the Taf coding region. The TGA (stop) codon for TrpE is "coupled" with the ATG (start) codon for the Taf gene, forming the sequence TGATG as it is coupled with the ATG (start) codon for TrpD on the E. coli chromosome. A one base frame-shift is required between translation of the short coding sequence and translation of the

25 Taf coding sequence.

In the example below, a fragment containing the T7 gene 10-E. coli TrpE/TrpD fusion product (the last 6 codons and TGA stop codon from TrpE along with the overlapping ATG start codon from TrpD) was obtained from a pre-existing plasmid. One of ordinary skill will recognize that the T7 gene 10-E. coli TrpE/TrpD fusion

30 product used in the construction of the translationally coupled expression vectors can be constructed from synthetic oligonucleotides. The sequence for the inserted fragment is listed below.

The T7 gene 10-E. coli TrpE/TrpD fusion product was amplified using plasmid pSYC1868 and primers FL48 and FL50. FL52 and FL54 were used to amplify the 5'

35 end of the Taf Pol I gene in pTaf02 from the ATG start codon to the BglII site downstream of the ATG start codon. The primers FL50 and FL52 were designed to be

partially complementary. Consequently, the extension product of FL48 can hybridize to the extension product of FL54. The two amplification products were mixed, heated to 95°C and slowly cooled to room temperature to anneal. Hybrids formed between the extension products of FL48 and FL54 were extended with Taq polymerase to form a full length double-stranded molecule.

The extended insert was amplified with primers FL48 and FL54 and then digested with MroI and BglII. Plasmid pTaf03 was digested with MroI and BglII, then treated with calf intestine alkaline phosphatase to prevent re-ligation. The digested pTaf03 was ligated with the insert. DG116 host cells were transformed with the resulting construct and transformants screened for the desired plasmid DNA. The resulting vector was designated pTaf15.

The sequences of the oligonucleotide primers and the T7 gene 10-E. coli TrpE/TrpD fusion product (gene 10 insert) are listed below.

	<u>Primers</u>	<u>SEQ ID NO:</u>	<u>Sequence</u>
15	FL48	SEQ ID NO: 53	5'-TCCGGACTTTAAGAAGGAGATATAC
	FL50	SEQ ID NO: 54	5'-AACATCTTACCCATCAGAAAGTCTCCTGTGC
	FL52	SEQ ID NO: 55	5'-AGACTTTCTGATGGGTAAGATGTTC
	FL54	SEQ ID NO: 56	5'-AACAAGTTGTAAAAGATCTTTATCTCCAG
20	Gene10 insert	SEQ ID NO: 57	5'-CTTTAAGAAGGAGATATACATATGGCTAG- CATGACTGGTGGACAGCAAATGCATGCACA- GGAGACTTTCTGATG

Example 10

Arg U tRNA Expression

The pattern of codon usage differs between Thermosipho africanus and E. coli. In the Taf coding sequence, arginine is most frequently coded for by the AGA codon, whereas this codon is used in low frequency in E. coli host cells. The corresponding Arg U tRNA appears in low concentrations in E. coli. The low concentration in the host cell of Arg tRNA using the AGA codon may limit the translation efficiency of the Taf polymerase gene. The efficiency of translation of the Taf coding sequence within an E. coli host may be improved by increasing the concentration of this tRNA species by cloning multiple copies of the tRNA gene into the host cell using a second expression vector that contains the gene for the "Arg U" tRNA.

The Arg U tRNA gene was PCR amplified from E. coli genomic DNA using the primers DG284 and DG285. The amplification product was digested with SalI and BamHI. The ColEI compatible vector pACYC184, commercially available from

New England Biolabs, was digested with Sall and BamHI, and the Arg U gene fragment was subsequently ligated with the digested vector. DG101 cells were transformed, and the ligated vector was designated pARG01. Finally, DG116 host cells were co-transformed with pARG01 and pTaf03.

5 The oligonucleotide primers used in this Example are listed below.

<u>Primers</u>	<u>SEQ ID NO:</u>	<u>Sequence</u>
DG284	SEQ ID NO: 58	5'-CGGGGATCCAAAAGCCATTGACTCAGCAAGG
DG285	SEQ ID NO: 59	5'-GGGGGTCGACGCATGCGAGGAAAATAGACG

Example 11

10

Purification of Recombinant Taf Polymerase

Recombinant Taf DNA Polymerase can be purified from the expression host/vector combinations described, for example, E. coli strain DG116 containing one of the expression vectors described in Example 4, above, using the following protocol.

15 The seed flask for a 10 L fermentation contains tryptone (20 g/l), yeast extract (10 g/l), NaCl (10 g/l), glucose (10 g/l), ampicillin (50 mg/l), and thiamine (10 mg/l). The seed flask is inoculated with a colony from an agar plate (a frozen glycerol culture can be used). The seed flask is grown at 30°C to between 0.5 to 2.0 O.D. (A_{680}). The volume of seed culture inoculated into the fermentor is calculated such that the bacterial concentration is 0.5 mg dry weight/liter. The 10 liter growth medium contains 25 mM
 20 KH_2PO_4 , 10 mM $(NH_4)_2SO_4$, 4 mM sodium citrate, 0.4 mM $FeCl_3$, 0.04 mM $ZnCl_2$, 0.03 mM $CoCl_2$, 0.03 mM $CuCl_2$, and 0.03 mM H_3BO_3 . The following sterile components are added: 4 mM $MgSO_4$, 20 g/l glucose, 20 mg/l thiamine, and 50 mg/l ampicillin. The pH is adjusted to 6.8 with NaOH and controlled during the fermentation by added NH_4OH . Glucose is continually added by coupling to NH_4OH addition.
 25 Foaming is controlled by the addition of propylene glycol as necessary, as an antifoaming agent. Dissolved oxygen concentration is maintained at 40%.

The fermentor is inoculated as described above, and the culture is grown at 30°C to a cell density of 0.5 to 1.0×10^{10} cells/ml (optical density [A_{680}] of 15). The growth temperature is shifted to between 37°C and 41°C to induce the synthesis of Taf
 30 DNA polymerase. The temperature shift increases the copy number of the expression plasmid and simultaneously derepresses the lambda P_L promoter controlling transcription of the modified Taf DNA polymerase gene through inactivation of the temperature-sensitive cI repressor encoded by the defective prophage lysogen in the host.

35 The cells are grown for 6 hours to an optical density of 37 (A_{680}) and harvested by centrifugation. The cell mass (ca. 95 g/l) is resuspended in an equivalent volume of

buffer containing 50 mM Tris-Cl, pH 7.6, 20 mM EDTA and 20% (w/v) glycerol. The suspension is slowly dripped into liquid nitrogen to freeze the suspension as "beads" or small pellets. The frozen cells are stored at -70°C.

To 200 g of frozen beads (containing 100 g wet weight cell) is added 100 ml of
5 1X TE (50 mM Tris-Cl, pH 7.5, 10 mM EDTA) and Dithiothreitol (DTT) to 0.3 mM, phenylmethanesulfonyl fluoride (PMSF) to 2.4 mM, leupeptin to 1 µg/ml and L-1-Chloro-3-[4-tosylamido]-7-amino-2-heptanone-HCl (TLCK) (the latter three are protease inhibitors) to 0.2 mM. The sample is thawed on ice and uniformly resuspended in a blender at low speed. The cell suspension is lysed in an Aminco
10 french pressure cell at 20,000 psi. To reduce viscosity, the lysed cell sample is sonicated 4 times for 3 min. each at 50% duty cycle and 70% output. The sonicate is adjusted to 550 ml with 1X TE containing 1 mM DTT, 2.4 mM PMSF, 1 µg/ml leupeptin and 0.2 mM TLCK (Fraction I). After addition of ammonium sulfate to 0.3 M, the crude lysate is rapidly brought to 75°C in a boiling water bath and transferred to
15 a 75°C water bath for 15 min. to denature and inactivate *E. coli* host proteins. The heat-treated sample is chilled rapidly to 0°C and incubated on ice for 20 min. Precipitated proteins and cell membranes are removed by centrifugation at 20,000 X G for 30 min. at 5°C and the supernatant (Fraction II) saved.

The heat-treated supernatant (Fraction II) is treated with polyethyleneimine
20 (PEI) to remove most of the DNA and RNA. Polymix P (34.96 ml of 10% [w/v], pH 7.5) is slowly added to 437 ml of Fraction II at 0°C while stirring rapidly. After 30 min. at 0°C, the sample is centrifuged at 20,000 X G for 30 min. The supernatant (Fraction III) is applied at 80 ml/hr to a 100 ml phenylsepharose column (3.2x12.5 cm) that has been equilibrated in 50 mM Tris-Cl, pH 7.5, 0.3 M ammonium sulfate, 10 mM
25 EDTA, and 1 mM DTT. The column is washed with about 200 ml of the same buffer (A₂₈₀ to baseline) and then with 150 ml of 50 mM Tris-Cl, pH 7.5, 100 mM KCl, 10 mM EDTA and 1 mM DTT. The *Taf* DNA polymerase is then eluted from the column with buffer containing 50 mM Tris-Cl, pH 7.5, 2 M urea, 20% (w/v) ethylene glycol, 10 mM EDTA, and 1 mM DTT, and fractions containing DNA polymerase activity are
30 pooled (Fraction IV).

Fraction IV is adjusted to a conductivity equivalent to 50 mM KCl in 50 mM Tris-Cl, pH 7.5, 1 mM EDTA, and 1 mM DTT. The sample is applied (at 9 ml/hr) to a 15 ml heparin-sepharose column that has been equilibrated in the same buffer. The column is washed with the same buffer at ca. 14 ml/hr (3.5 column volumes) and
35 eluted with a 150 ml 0.05 to 0.75 M KCl gradient in the same buffer. Fractions containing the *Taf* DNA polymerase are pooled, concentrated, and diafiltered against 2.5X storage buffer (50 mM Tris-Cl, pH 8.0, 250 mM KCl, 0.25 mM EDTA, 2.5 mM

DTT, and 0.5% Tween 20), subsequently mixed with 1.5 volumes of sterile 80% (w/v) glycerol, and stored at -20°C.

Optionally, the heparin sepharose-eluted DNA polymerase or the phenyl sepharose-eluted DNA polymerase can be dialyzed or adjusted to a conductivity equivalent to 50 mM KCl in 50 mM Tris-Cl, pH 7.5, 1 mM DTT, 1 mM EDTA, and 0.2% Tween 20 and subjected to nucleotide binding protein affinity chromatography. The polymerase containing extract is applied (1 mg protein/ml resin) to an affigel blue column that has been equilibrated in the same buffer. The column is washed with three to five column volumes of the same buffer and eluted with a 10 column volume KCl gradient (0.05 to 0.8 M) in the same buffer. Fractions containing DNA polymerase activity are pooled, concentrated, diafiltered, and stored as above.

Optionally, the pooled fractions can be subjected to cation exchange chromatography. The fractions are applied to a 2 ml CM-Tris-Acryl M (LKB) column equilibrated with a buffer consisting of 25 mM sodium acetate, 20 mM NaCl, 0.1 mM EDTA, 1 mM DTT, and 0.2% Tween 20 at pH 5.0. The column is washed with 4-5 column volumes of the same buffer and the enzyme eluted with a linear gradient from 20 to 400 mM NaCl in sodium acetate buffer. Active fractions are pooled, concentrated, diafiltered, and stored as above.

Deposits

The following deposit was made on the date given:

Strain

Deposit Date

ATCC No.

pTaf02

- 5 This deposit was made under the provisions of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure and the Regulations thereunder (Budapest Treaty). This assures maintenance of a viable culture for 30 years from date of deposit. The organism will be made available by ATCC under the terms of the Budapest Treaty, and subject to an
- 10 agreement between Applicants and ATCC, which assures permanent and unrestricted availability of the progeny of the cultures to the public upon issuance of the pertinent U.S. patent or upon laying open to the public of any U.S. or foreign patent application, whichever comes first, and assures availability of the progeny to one determined by the U.S. Commissioner of Patents and Trademarks to be entitled thereto according to
- 15 U.S.C. §122 and the Commissioner's rules pursuant thereto (including 37 C.F.R. §1.14 with particular reference to 886 OG 638). The assignee of the present application agrees that if the culture on deposit should die or be lost or destroyed when cultivated under suitable conditions, it will be promptly replaced on notification with a viable specimen of the same culture. Availability of the deposited strain is not to be
- 20 construed as a license to practice the invention in contravention of the rights granted under the authority of any government in accordance with its patent laws.

We Claim

1. A purified thermostable DNA polymerase I enzyme that catalyzes combination of nucleoside triphosphates to form a nucleic acid strand complementary to a nucleic acid template strand, said enzyme derived from the eubacterium Thermosiphon africanus.
2. The enzyme of Claim 1 that has reverse transcriptase activity.
3. The enzyme of Claim 1 that has 5'→3' exonuclease activity.
4. The enzyme of Claim 1 that has 3'→5' exonuclease activity.
5. A method for purifying Thermosiphon africanus DNA polymerase I, said method comprising the steps of:
 - (a) preparing a crude cell extract from cells that produce said polymerase;
 - (b) adjusting the ionic strength of said extract so that said polymerase dissociates from any nucleic acid in said extract; and
 - (c) subjecting the extract to at least one step selected from the group consisting of: hydrophobic interaction, DNA binding protein affinity, nucleotide binding protein affinity, anion exchange, cation exchange, and hydroxyapatite chromatography step.
6. A recombinant DNA consisting essentially of a nucleotide sequence that encodes Taf DNA polymerase I activity.
7. The DNA of Claim 6 that encodes the amino acid sequence from amino to carboxy terminus:

MetGlyLysMetPheLeu

PheAspGlyThrGlyLeuValTyrArgAlaPheTyrAlaIleAsp
 GlnSerLeuGlnThrSerSerGlyLeuHisThrAsnAlaValTyr
 GlyLeuThrLysMetLeuIleLysPheLeuLysGluHisIleSer
 IleGlyLysAspAlaCysValPheValLeuAspSerLysGlyGly
 SerLysLysArgLysAspIleLeuGluThrTyrLysAlaAsnArg
 ProSerThrProAspLeuLeuLeuGluGlnIleProTyrValGlu
 GluLeuValAspAlaLeuGlyIleLysValLeuLysIleGluGly
 PheGluAlaAspAspIleIleAlaThrLeuSerLysLysPheGlu

SerAspPheGluLysValAsnIleIleThrGlyAspLysAspLeu
LeuGlnLeuValSerAspLysValPheValTrpArgValGluArg
GlyIleThrAspLeuValLeuTyrAspArgAsnLysValIleGlu
LysTyrGlyIleTyrProGluGlnPheLysAspTyrLeuSerLeu
5 ValGlyAspGlnIleAspAsnIleProGlyValLysGlyIleGly
LysLysThrAlaValSerLeuLeuLysLysTyrAsnSerLeuGlu
AsnValLeuLysAsnIleAsnLeuLeuThrGluLysLeuArgArg
LeuLeuGluAspSerLysGluAspLeuGlnLysSerIleGluLeu
ValGluLeuIleTyrAspValProMetAspValGluLysAspGlu
10 IleIleTyrArgGlyTyrAsnProAspLysLeuLeuLysValLeu
LysLysTyrGluPheSerSerIleIleLysGluLeuAsnLeuGln
GluLysLeuGluLysGluTyrIleLeuValAspAsnGluAspLys
LeuLysLysLeuAlaGluGluIleGluLysTyrLysThrPheSer
IleAspThrGluThrThrSerLeuAspProPheGluAlaLysLeu
15 ValGlyIleSerIleSerThrMetGluGlyLysAlaTyrTyrIle
ProValSerHisPheGlyAlaLysAsnIleSerLysSerLeuIle
AspLysPheLeuLysGlnIleLeuGlnGluLysAspTyrAsnIle
ValGlyGlnAsnLeuLysPheAspTyrGluIlePheLysSerMet
GlyPheSerProAsnValProHisPheAspThrMetIleAlaAla
20 TyrLeuLeuAsnProAspGluLysArgPheAsnLeuGluGluLeu
SerLeuLysTyrLeuGlyTyrLysMetIleSerPheAspGluLeu
ValAsnGluAsnValProLeuPheGlyAsnAspPheSerTyrVal
ProLeuGluArgAlaValGluTyrSerCysGluAspAlaAspVal
ThrTyrArgIlePheArgLysLeuGlyArgLysIleTyrGluAsn
25 GluMetGluLysLeuPheTyrGluIleGluMetProLeuIleAsp
ValLeuSerGluMetGluLeuAsnGlyValTyrPheAspGluGlu
TyrLeuLysGluLeuSerLysLysTyrGlnGluLysMetAspGly
IleLysGluLysValPheGluIleAlaGlyGluThrPheAsnLeu
AsnSerSerThrGlnValAlaTyrIleLeuPheGluLysLeuAsn
30 IleAlaProTyrLysLysThrAlaThrGlyLysPheSerThrAsn
AlaGluValLeuGluGluLeuSerLysGluHisGluIleAlaLys
LeuLeuLeuGluTyrArgLysTyrGlnLysLeuLysSerThrTyr
IleAspSerIleProLeuSerIleAsnArgLysThrAsnArgVal
HisThrThrPheHisGlnThrGlyThrSerThrGlyArgLeuSer
35 SerSerAsnProAsnLeuGlnAsnLeuProThrArgSerGluGlu
GlyLysGluIleArgLysAlaValArgProGlnArgGlnAspTrp
TrpIleLeuGlyAlaAspTyrSerGlnIleGluLeuArgValLeu

AlaHisValSerLysAspGluAsnLeuLeuLysAlaPheLysGlu
AspLeuAspIleHisThrIleThrAlaAlaLysIlePheGlyVal
SerGluMetPheValSerGluGlnMetArgArgValGlyLysMet
ValAsnPheAlaIleIleTyrGlyValSerProTyrGlyLeuSer
5 LysArgIleGlyLeuSerValSerGluThrLysLysIleIleAsp
AsnTyrPheArgTyrTyrLysGlyValPheGluTyrLeuLysArg
MetLysAspGluAlaArgLysLysGlyTyrValThrThrLeuPhe
GlyArgArgArgTyrIleProGlnLeuArgSerLysAsnGlyAsn
ArgValGlnGluGlyGluArgIleAlaValAsnThrProIleGln
10 GlyThrAlaAlaAspIleIleLysIleAlaMetIleAsnIleHis
AsnArgLeuLysLysGluAsnLeuArgSerLysMetIleLeuGln
ValHisAspGluLeuValPheGluValProAspAsnGluLeuGlu
IleValLysAspLeuValArgAspGluMetGluAsnAlaValLys
LeuAspValProLeuLysValAspValTyrTyrGlyLysGluTrp
15 Glu, which is SEQ ID: 2.

8. The DNA of Claim 7 that is SEQ ID NO: 3:

5' -ATGGGAAAGATGTTTCTA
TTTGATGGAACCTGGATTAGTATACAGAGCATTTTATGCTATAGAT
20 CAATCTCTTCAAACCTTCGTCTGGTTTACACACTAATGCTGTATAC
GGACTTACTAAAATGCTTATAAAATTTTTAAAAGAACATATCAGT
ATTGGAAAAGATGCTTGTGTTTTTGTTTTAGATTCAAAGGTGGT
AGCAAAAAAAGAAAGGATATTCTTGAAACATATAAAGCAAATAGG
CCATCAACGCCTGATTTACTTTTAGAGCAAATTCCATATGTAGAA
25 GAACTTGTTGATGCTCTTGGAATAAAAGTTTTAAAATAGAAGGC
TTTGAAGCTGATGACATTATTGCTACGCTTCTAAAAAATTTGAA
AGTGATTTTGAAAAGGTAAACATAATAACTGGAGATAAAGATCTT
TTACAACCTGTTTCTGATAAGGTTTTTGTGTTGGAGAGTAGAAAGA
GGAATAACAGATTTGGTATTGTACGATAGAAATAAAGTGATTGAA
30 AAATATGGAATCTACCCAGAACAATTCAAAGATTATTTATCTCTT
GTCGGTGATCAGATTGATAATATCCAGGAGTTAAAGGAATAGGA
AAGAAAACAGCTGTTTCGCTTTTGAAAAAATATAATAGCTTGGA
AATGTATTAAAAAATATTAACCTTTTGACGGAAAAATTAAGAAGG
CTTTTGGAAGATTCAAAGGAAGATTTGCAAAAAGTATAGAAGCTT
35 GTGGAGTTGATATATGATGTACCAATGGATGTGGAAAAAGATGAA
ATAATTTATAGAGGGTATAATCCAGATAAGCTTTTAAAGGTATTA
AAAAAGTACGAATTTTCATCTATAATTAAGGAGTTAAATTTACAA

5 GAAAAATTAGAAAAGGAATATATACTGGTAGATAATGAAGATAAA
TTGAAAAAACTTGCAGAAGAGATAGAAAAATACAAAACCTTTTCA
ATTGATACGGAAACAACCTTCACTTGATCCATTTGAAGCTAAACTG
GTTGGGATCTCTATTTCCACAATGGAAGGGAAGGCGTATTATATT
CCGGTGTCTCATTTTGGAGCTAAGAATATTTCCAAAAGTTTAATA
GATAAATTTCTAAAACAAATTTTGCAAGAGAAGGATTATAATATC
GTTGGTCAGAATTTAAAATTTGACTATGAGATTTTTAAAAGCATG
GGTTTTTCTCCAAATGTTCCGCATTTTGATACGATGATTGCAGCC
TATCTTTTAAATCCAGATGAAAAACGTTTTAATCTTGAAGAGCTA
10 TCCTTAAAATATTTAGGTTATAAAATGATCTCGTTTGATGAATTA
GTAAATGAAAATGTACCATTGTTTGGAAATGACTTTTCGTATGTT
CCACTAGAAAGAGCCGTTGAGTATTCCTGTGAAGATGCCGATGTG
ACATACAGAATATTTAGAAAGCTTGGTAGGAAGATATATGAAAAT
GAGATGGAAAAGTTGTTTTACGAAATTGAGATGCCCTTAATTGAT
15 GTTCTTTCAGAAATGGAACATAATGGAGTGTATTTTGATGAGGAA
TATTTAAAAGAATTATCAAAAAATATCAAGAAAAATGGATGGA
ATTAAGGAAAAAGTTTTTGAGATAGCTGGTGAAACTTTCAATTTA
AACTCTTCAACTCAAGTAGCATATATACTATTTGAAAAATTAAAT
ATTGCTCCTTACAAAAAACAGCGACTGGTAAGTTTTCAACTAAT
20 GCGGAAGTTTTAGAGAAGCTTTCAAAGAACATGAAATTGCAAAA
TTGTTGCTGGAGTATCGAAAGTATCAAAAATTAAAAGTACATAT
ATTGATTCAATACCGTTATCTATTAATCGAAAAACAAACAGGGTC
CATACTACTTTTCATCAAACAGGAACCTTCTACTGGAAGATTAAGT
AGTTCAAATCCAAATTTGCAAAATCTTCCAACAAGAAGCGAAGAA
25 GGAAAAGAAATAAGAAAAGCAGTAAGACCTCAAAGACAAGATTGG
TGGATTTTAGGTGCTGACTATTCTCAGATAGAAGTAAGGGTTTTA
GCGCATGTAAGTAAAGATGAAAATCTACTTAAAGCATTTAAGAA
GATTTAGATATTCATACAATTACTGCTGCCAAAATTTTTGGTGTT
TCAGAGATGTTTGTAGTGAACAAATGAGAAGAGTTGGAAAGATG
30 GTAAATTTTGCAATTATTTATGGAGTTTCACCTTATGGTCTTTCA
AAGAGAATTGGTCTTAGTGTTTCAGAGACTAAAAAATAATAGAT
AACTATTTTAGATACTATAAAGGAGTTTTTGAATATTTAAAAGG
ATGAAAGATGAAGCAAGGAAAAAAGGTTATGTTACAACGCTTTTT
GGAAGGCGCAGATATATTCCACAGTTAAGATCGAAAAATGGTAAT
35 AGAGTTCAAGAAGGAGAAAGAATAGCTGTAAACACTCCAATTCAA
GGAACAGCAGCTGATATAATAAAGATAGCTATGATTAATATTCAT
AATAGATTGAAGAAGGAAAATCTACGTTCAAAAATGATATTGCAG

G TTCATGACGAGTTAGTTTTTGAAGTGCCCGATAATGAACTGGAG
ATTGTAAGAGATTTAGTAAGAGATGAGATGGAAAATGCAGTTAAG
CTAGACGTTCCCTTTAAAAGTAGATGTTTATTATGGAAAAGAGTGG
GAATAA

5

9. A recombinant DNA vector that comprises the DNA sequence of claim 6.

10. The recombinant DNA vector of Claim 9 that is a plasmid selected from the group consisting of pTaf01, pTap02, pTaf03, pTaf04, pTaf05, pTaf06, pTaf07, pTaf08, pTaf13, pTaf14, pTaf15, pTaf16, and pBSM:TafEcoRV.

10

11. A recombinant DNA consisting essentially of a nucleotide sequence that encodes the amino acid sequence consisting of amino acids 1 and 94 through 892 of SEQ ID NO: 2.

15

12. A recombinant DNA consisting essentially of a nucleotide sequence that encodes the amino acid sequence consisting of amino acids 1 and 140 through 892 of SEQ ID NO: 2.

20

13. A recombinant DNA vector that comprises the DNA of Claim 11.

14. A recombinant DNA vector that comprises the DNA of Claim 12.

15. A recombinant DNA vector of Claim 13 that is selected from the group consisting of pTaf09 and pTaf10.

25

16. A recombinant DNA vector of Claim 14 that is selected from the group consisting of pTaf11 and pTaf12.

30

17. A recombinant host cell transformed with a vector of Claim 9.

18. The recombinant host cell of Claim 17 that is E. coli.

19. The DNA of Claim 7 which has been mutated to cause the resultant polymerase activity to lack 5'→3' exonuclease activity.


35

20. The DNA of Claim 19 in which the mutation is a substitution of an Asp codon for the Gly codon at position 37.



21. The DNA of Claim 19 in which the mutation is a deletion up to and
5 including the Gly codon at codon 37.

1 / 3



PROFILE 1: ON CHROMOSOMAL DNA



PROFILE 2: ON PURIFIED ACRYLAMIDE FRAGMENT

PROFILE 3: ON LOWMELTING AGAROSE FRAGMENT
CHROMOSOMAL AMPLIFICATION IDENTICAL TO PROFILE 1

PROFILE 4: ON LOW MELTING AGAROSE FRAGMENT


PROFILE 5: ON LOW MELTING AGAROSE FRAGMENT
IDENTICAL TO CHROMOSOME

OB-7
DGI54-DGI55 + DGI60-DGI63

FIG. 1

2 / 3

FIG. 2




LANE AMPLIFICATION OB7
DGI54DGI55 + DGI60-DGI63


1 2 3 4 5 6 7 8 9 10
PBR322 MspI DIGEST
TEMPERATURE
PROFILE NUMBER

3 / 3


PROFILE 1




PROFILE 2




PROFILE 3



PROFILE 4



PROFILE 5



PROFILE 6




FIG. 3

SUBSTITUTE SHEET

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 91/07076

I. CLASSIFICATION OF SUBJECT MATTER (If several classification symbols apply, indicate all)⁶

According to International Patent Classification (IPC) or to both National Classification and IPC

Int. Cl. 5 C 12 N 15/54 C 12 N 9/12 C 12 N 1/21 //
(C 12 N 1/21 C 12 R 1:21)

II. FIELDS SEARCHED

Minimum Documentation Searched⁷

Classification System

Classification Symbols

Int. Cl. 5

C 12 N

Documentation Searched other than Minimum Documentation
to the Extent that such Documents are Included in the Fields Searched⁸

III. DOCUMENTS CONSIDERED TO BE RELEVANT⁹

Category ¹⁰	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³
A	System. Appl. Microbiol., vol. 12, no. 1, January 1989, Fischer, Stuttgart (DE) R. Huber et al.: "Thermosipho africanus gen. nov., Represents a new genus of thermophilic eubacteria within the "Thermotogales", pages 32-37, see abstract (cited in the application) ---	1-21
A	The Journal of Biological Chemistry, vol. 264, no. 11, 15 April 1989, Am. Soc. for Biochem. and Mol. Biol. Inc. (US) F.C. Lawyer et al.: "Isolation, characterization, and expression in Escherichia coli of the DNA polymerase gene from Thermus aquaticus", pages 6427-6437, see page 6427, right-hand column, line 18 - page 6431, left-hand column, line 5 --- -/-	1-21

¹⁰ Special categories of cited documents : ¹⁰

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"A" document member of the same patent family

IV. CERTIFICATION

Date of the Actual Completion of the International Search

12-02-1992

Date of Mailing of this International Search Report

16. 03. 92

International Searching Authority

EUROPEAN PATENT OFFICE

Signature of Authorized Officer

Maria Peis

Mark Peis

III. DOCUMENTS CONSIDERED TO BE RELEVANT

(CONTINUED FROM THE SECOND SHEET)

Category *	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No.
A	Proc. Natl. Acad. Sci, vol. 86, no. 12, June 1989, National Acad. Sciences, Washington, DC (US) M.C. Leavitt et al.: "T5 DNA polymerase: structural-functional relationships to other DNA polymerases", pages 4465-4469, see figure 4; page 4468, lines 13-35 -----	19,20, 21
A	Cell, vol. 59, no. 1, 6 October 1989, Cell Press, MA (US), A. Bernad et al.: "A conserved 3'-5' exonuclease active site in prokaryotic and eukaryotic DNA polymerases", pages 219-228, see figure 5; page 224, right-hand column, line 6 - page 225, left-hand column, line 26 -----	19,20, 21